Enzymotec (ENZY) 20-F/A 18 Feb 14 2013 FY Annual report (foreign) (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2013
Document And Entity Information [Abstract]	'
Document Type	'20-F/A
Amendment Flag	'false
Document Period End Date	31-Dec-13
Entity Registrant Name	'Enzymotec Ltd.
Entity Central Index Key	'0001578809
Current Fiscal Year End Date	'--12-31
Document Fiscal Period Focus	'FY
Document Fiscal Year Focus	'2013
Entity Filer Category	'Non-accelerated Filer
Entity Well-known Seasoned Issuer	'No
Entity Current Reporting Status	'Yes
Entity Common Stock, Shares Outstanding	21,564,820

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$74,430	$2,729
Accounts receivable:	'	'
Trade	18,788	11,204
Other	2,738	3,357
Inventories	11,943	9,359
Total current assets	107,899	26,649
NON-CURRENT ASSETS:	'	'
Investment in equity investee	809	307
Long-term deposits and other	111	170
Funds in respect of retirement benefits obligation	1,190	880
Total non-current assets	2,110	1,357
PROPERTY, PLANT AND EQUIPMENT:	'	'
Cost	33,385	28,468
Less - accumulated depreciation and amortization	7,021	5,504
Net	26,364	22,964
Total assets	136,373	50,970
CURRENT LIABILITIES:	'	'
Short-term loans and current maturity of long-term loans	4,200	1,700
Accounts payable and accruals:	'	'
Trade	6,418	6,764
Other	6,378	3,082
Total current liabilities	16,996	11,546
NON-CURRENT LIABILITIES:	'	'
Retirement benefits obligation	1,474	1,043
Long-term loans, net of current maturity	'	4,200
Total long-term liabilities	1,474	5,243
COMMITMENTS AND CONTINGENCIES (Note 9)	'	'
Total liabilities	18,470	16,789
SHAREHOLDERS' EQUITY:	'	'
Ordinary shares of NIS 0.01 par value at December 31, 2013 and 2012: authorized - 100,000,000 shares and 3,399,618 shares, respectively; issued and outstanding 21,564,820 shares and 2,996,624 shares, respectively.	55	8
Preferred shares	'	'
Additional paid-in capital	119,547	47,449
Accumulated other comprehensive loss	-65	-247
Accumulated deficit	-1,634	-13,029
Total shareholders' equity	117,903	34,181
Total liabilities and shareholders' equity	136,373	50,970
Series A Preferred Stock [Member]	'	'
SHAREHOLDERS' EQUITY:	'	'
Preferred shares	'	'	[1]
Series B Preferred Stock [Member]	'	'
SHAREHOLDERS' EQUITY:	'	'
Preferred shares	'	'	[1]
Series B1 Preferred Stock [Member]	'	'
SHAREHOLDERS' EQUITY:	'	'
Preferred shares	'	'	[1]
Series B2 Preferred Stock [Member]	'	'
SHAREHOLDERS' EQUITY:	'	'
Preferred shares	'	'	[1]
[1]	Represents an amount of less than $1,000.

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (ILS)	Dec. 31, 2013	Dec. 31, 2012
Ordinary shares, par value per share	0.01	0.01
Ordinary shares, shares authorized	100,000,000	3,399,618
Ordinary shares, shares issued	21,564,820	2,996,624
Ordinary shares, shares outstanding	21,564,820	2,996,624
Series A Preferred Stock [Member]	'	'
Preferred stock, par value per share	0.01	0.01
Preferred stock, shares authorized	'	8,282
Preferred stock, shares issued	'	8,282
Series B Preferred Stock [Member]	'	'
Preferred stock, par value per share	0.01	0.01
Preferred stock, shares authorized	'	15,000
Preferred stock, shares issued	'	9,952
Series B1 Preferred Stock [Member]	'	'
Preferred stock, par value per share	0.01	0.01
Preferred stock, shares authorized	'	152,100
Preferred stock, shares issued	'	131,088
Series B2 Preferred Stock [Member]	'	'
Preferred stock, par value per share	0.01	0.01
Preferred stock, shares authorized	'	50,000
Preferred stock, shares issued	'	21,606

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) [Abstract]	'	'	'
NET REVENUES	$64,975	$37,867	$23,019
COST OF REVENUES	-32,110	-19,815	-13,468
GROSS PROFIT	32,865	18,052	9,551
OPERATING EXPENSES:	'	'	'
Research and development- net	-5,947	-4,611	-3,860
Selling and marketing	-6,725	-5,191	-3,580
General and administrative	-8,434	-2,935	-2,458
TOTAL OPERATING EXPENSES	-21,106	-12,737	-9,898
OPERATING INCOME (LOSS)	11,759	5,315	-347
FINANCIAL EXPENSES - net	-531	-539	-416
INCOME (LOSS) BEFORE TAXES ON INCOME	11,228	4,776	-763
TAXES ON INCOME	-324	-180	-137
SHARE IN PROFITS OF EQUITY INVESTEE	491	186	36
NET INCOME (LOSS)	11,395	4,782	-864
OTHER COMPREHENSIVE INCOME (LOSS):	'	'	'
Currency translation adjustments	11	14	-4
Changes in unrealized gains or losses in respect of derivative instruments designated for cash flow hedge	171	92	-45
TOTAL COMPREHENSIVE INCOME (LOSS)	$11,577	$4,888	($913)
EARNINGS (LOSS) PER SHARE:	'	'	'
Basic	$0.66	$0.33	($0.29)
Diluted	$0.53	$0.28	($0.29)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTATION OF EARNINGS (LOSS) PER SHARE:	'	'	'
Basic	7,544,387	2,996,624	2,965,481
Diluted	9,286,456	3,461,877	2,965,481

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (USD $)	Total		Ordinary shares [Member]		Preferred shares [Member]		Additional paid-in capital [Member]	Accumulated other comprehensive (loss) [Member]	Accumulated deficit [Member]
In Thousands, except Share data
Balance at Dec. 31, 2010	$23,034		$8		'	[1]	$40,277	($304)	($16,947)
Balance, shares at Dec. 31, 2010	'		2,945,352		149,322		'	'	'
Comprehensive income (loss)	-913		'		'		'	-49	-864
Issuance of B2 preferred shares and warrants, net of issuance costs	5,017		'		'	[1]	5,017	'	'
Issuance of B2 preferred shares and warrants, net of issuance costs, shares	'		'		17,479		'	'	'
Share-based compensation expense	343		'		'		343	'	'
Exercise of options by employees	48		'	[1]	'		48	'	'
Exercise of options by employees, shares	51,272		51,272		'		'	'	'
Balance at Dec. 31, 2011	27,529		8		'	[1]	45,685	-353	-17,811
Balance, shares at Dec. 31, 2011	'		2,996,624		166,801		'	'	'
Comprehensive income (loss)	4,888		'		'		'	106	4,782
Issuance of B2 preferred shares and warrants, net of issuance costs	1,497		'		'	[1]	1,497	'	'
Issuance of B2 preferred shares and warrants, net of issuance costs, shares	'		'		4,127		'	'	'
Share-based compensation expense	267		'		'		267	'	'
Exercise of options by employees, shares	'		'		'		'	'	'
Balance at Dec. 31, 2012	34,181		8		'	[1]	47,449	-247	-13,029
Balance, shares at Dec. 31, 2012	2,996,624		2,996,624		170,928		'	'	'
Comprehensive income (loss)	11,577		'		'		'	182	11,395
Issuance of B2 preferred shares and warrants, net of issuance costs	6,850		'		'	[1]	6,850	'	'
Issuance of B2 preferred shares and warrants, net of issuance costs, shares	'		'		18,856		'	'	'
Share-based compensation expense	1,109		'		'		1,109	'	'
Exercise of options by employees	8		'	[1]	'		8	'	'
Exercise of options by employees, shares	47,940		47,940		'		'	'	'
Exercise of warrants	1,340		'		'	[1]	1,340	'	'
Exercise of warrants, shares	'		'		5,663		'	'	'
Conversion of preferred shares to ordinary shares and bonus share distribution	'		33		'	[1]	-33	'	'
Conversion of preferred shares to ordinary shares and bonus share distribution, shares	'		13,290,396		-195,477		'	'	'
Issuance of ordinary shares in an initial public offering, net of issuance costs	62,838		14		'		62,824	'	'
Issuance of ordinary shares in an initial public offering, net of issuance costs, shares	'		5,073,800		'		'	'	'
Issuance of restricted shares	'	[1]	'	[1]	'		'	'	'
Issuance of restricted shares, shares	'		156,060		'		'	'	'
Balance at Dec. 31, 2013	$117,903		$55		'		$119,547	($65)	($1,634)
Balance, shares at Dec. 31, 2013	21,564,820		21,564,820		'		'	'	'
[1]	Represents an amount of less than $1,000.

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net Income (loss)	$11,395	$4,782	($864)
Adjustments required to reflect cash flows from operations:	'	'	'
Depreciation and amortization	1,551	1,422	1,233
Change in inventories	-2,584	-3,100	-202
Change in accounts receivable	-6,965	-3,806	-3,892
Change in accounts payable and accruals	3,052	3,590	853
Share in profits of equity investee	-491	-186	-36
Share-based compensation expense	1,109	267	343
Gain on sale of property, plant and equipment	-3	'	'
Change in other non-current assets	49	9	94
Change in retirement benefits obligation	277	45	96
Net cash provided by (used in) operating activities	7,390	3,023	-2,375
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchase of property, plant and equipment	-4,885	-1,248	-1,515
Long-term deposits	10	16	-12
Proceeds from the sale of property, plant and equipment	6	'	'
Change in funds in respect of retirement benefits obligation	-156	-46	-56
Net cash used in investing activities	-5,025	-1,278	-1,583
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Change in short-term loans	-1,000	-4,600	2,400
Repayment of long-term bank loan	-700	-700	-700
Proceeds from exercise of options by employees	8	'	48
Proceeds from exercise of warrants	1,340	'	'
Proceeds from initial public offering, net of issuance costs of $8.2 million	62,838	'	'
Proceeds from issuance of equity and warrants	6,850	1,497	5,017
Net cash (used in) provided by financing activities	69,336	-3,803	6,765
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	71,701	-2,058	2,807
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	2,729	4,787	1,980
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	74,430	2,729	4,787
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:	'	'	'
Interest paid	385	544	540
Income taxes paid, net of refunds	161	135	128
Supplementary information on financing and investing activities not involving cash flows	'	'	'
Amount included in trade payables in respect of acquisition of property, plant and equipment	$632	$563	$191

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]	'
Stock issuance costs	$8.20

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
	The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in United States ("U.S. GAAP"). The significant accounting policies were applied on a consistent basis, as follows:
		a.	General
	Enzymotec Ltd. (the "Company" or "Enzymotec"), an Israeli company formed in 1998, which, together with its subsidiaries, develops, manufactures, markets and sells innovative bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies.
	The Company's sales are made to companies that market dietary supplements, to distributors related to those companies, to nutrition companies that provide balanced nutrition to babies and to pharmaceutical companies that market the products as treating diseases by providing the body with optimal amounts of substances which are natural to the body. In the VAYA Pharma segment, the majority of the products are sold directly to customers in the US through wholesalers. Outside the US, sales are made through leading pharmaceutical companies. As to sales by geographic locations and major customers, see Note 5.
	In June 2007, the Company entered into a joint collaboration agreement with a Swedish vegetable oil company (the "Partner") for the manufacture, marketing and sale of products to the infant food industry and established Advance Lipids AB, a Swedish company jointly owned by both parties in equal proportions ("Advanced Lipids") for this purpose.
		b.	Basis of presentation
	On September 12, 2013, the Company effected a bonus share distribution under which: (i) 67 bonus shares were issued for each share outstanding prior to such distribution; and (ii) the conversion rate for each preferred share, option and warrant was adjusted to reflect such bonus share distribution. For accounting purposes, this transaction was recorded as a share split and accordingly (unless otherwise noted), all shares, options, warrants and earnings (losses) per share amounts have been adjusted retroactively for all years presented in these consolidated financial statements.
		c.	Use of estimates in preparation of financial statements
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to contingencies.
		d.	Functional currency
	The U.S. dollar ("dollar") is the currency of the primary economic environment in which the operations of the Company are conducted. The majority of the Company's sales are denominated in dollars; the majority of the Company's expenses are incurred in dollars; and the majority of the Company's financing has been provided in dollars.
	Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the consolidated statements of operations and comprehensive income (loss) (indicated below), the following exchange rates are used: (i) for transactions - exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are recorded in financial income (expenses), as appropriate.
	The functional currency of the Company's equity investee, Advanced Lipids, is the Swedish Krona, which is the currency of the primary economic environment in which the operations of Advanced Lipids are conducted. Currency translation adjustments are presented within other comprehensive income (loss).
		e.	Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been fully eliminated. Profits from intercompany sales have also been eliminated.
		f.	Investment in equity investee
	The Company's investment in Advanced Lipids, which is a less-than-majority-owned entity in which the Company exercises significant influence over operating and financial policies, is accounted for using the equity method of accounting. Under the equity method, original investments are recorded at cost and adjusted by the Company's share of undistributed profits or losses of such company. The Company's profits from Advanced Lipids have been reflected as "share in profits of equity investee" in the consolidated statements of operations and comprehensive income (loss).
		g.	Cash equivalents
	The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that are not restricted as to withdrawal or use, to be cash equivalents.
		h.	Inventories
	Inventories include raw materials and finished products and are valued at the lower of cost or market. The cost of inventories is determined as follows:
	Raw materials and supplies - on the "first-in, first-out" basis;
	Products in process and finished products: the raw and packaging materials on the "first-in, first-out" basis; the capitalized production cost - mainly on an average basis over the production period.
		i.	Property, plant and equipment
	These assets are stated at cost, net of accumulated depreciation and amortization. The assets are depreciated by the straight-line method on the basis of their estimated useful lives.
	Annual rates of depreciation are as follows:
			%
	Computers and software			33
	Buildings			2
	Vehicles			15
	Manufacturing equipment			7 - 10
	Laboratory equipment (mainly 15%)			7 - 20
	Furniture and office equipment			6 - 15
	Leasehold improvements are amortized by the straight-line method over the term of the lease, which is shorter than the estimated useful life of the improvements.
		j.	Impairment of long-lived assets
	The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the assets is less than the carrying amount of such assets, an impairment loss would be
	recognized. The assets would be written down to their estimated fair values, calculated based on the present value of expected future cash flows (discounted cash flows), or some other fair value measure.
	As of December 31, 2013, 2012 and 2011, the Company did not recognize an impairment loss for its long-lived assets.
		k.	Revenue recognition
	The Company recognizes revenue from sales of its products to customers, including distributors, when persuasive evidence of sales arrangement exists, delivery has occurred, the sales price is fixed or determinable and collectability is reasonably assured. See also Note 4 for timing of revenue recognition related to the Company's joint collaboration agreement. The Company provides a right of return to its U.S. distributors upon expiry of the medical food products sold in the Vaya Pharma segment. Accordingly, the Company records a reserve for estimated sales returns based on historical experience since the beginning of 2011, as well as specific factors, such as levels of inventory in the distribution channel, product dating and expiration. Returns to date have been inconsequential. Revenues from product sales are also recorded net of cash discounts and distribution fees, which can be reasonably estimated.
		l.	Research and development expenses
	Research and development expenses are charged to income as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. The main components of the research and development expenses are salaries and related expenses, laboratory, clinical research and regulatory related expenses.
		m.	Contingencies
	Certain conditions may exist as of the date of the financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. Management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	Management applies the guidance in Accounting Standards Codification ("ASC") 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material are disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantees are disclosed.
		n.	Income taxes
	Deferred income taxes are determined by the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the tax rates expected to be in effect at the time when these differences reverse. Valuation allowances in respect of the deferred tax assets are provided when it is more likely than not that all or a portion of the deferred income tax assets will not be realized. See Note 12g for additional information regarding deferred taxes.
	The Company assesses its valuation allowance considering different indicators, including profitability of the different entities in the different tax jurisdictions, the ability to utilize the deferred tax assets in subsequent years, etc.
	Upon the distribution of dividends from the tax-exempt income of an "Approved Enterprise" or "Benefitted Enterprise" (see also Note 12 a (3)), the amount distributed is subject to tax at the rate that would have been applicable had the Company not been exempted from payment thereof. The Company intends to permanently reinvest the amounts of tax exempt income and it does not intend to distribute such dividends. Therefore, no deferred income taxes have been provided in respect of such tax-exempt income.
	The Company may incur an additional tax liability in the event of an inter-company dividend distribution from foreign subsidiaries; no additional deferred income taxes have been provided, since it is the Company's policy not to distribute dividends in the foreseeable future that may result in additional tax liability.
	Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been taken into account in computing deferred income taxes, as it is the Company's intent and ability to hold these investments.
	Tax benefits recognized in the consolidated financial statements are those that management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit management deems more likely than not to be sustained.
		o.	Share-based compensation
	The Company accounts for employees and directors share-based compensation awards classified as equity awards using the grant-date fair value method. The fair value of share-based compensation transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. Performance-based awards are expensed over the requisite service period based on achievement of performance criteria.
	The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the straight-line method based on the multiple-option award approach.
	When options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
		p.	Shipping and handling costs
	Shipping and handling costs on sales are classified as a component of cost of revenues.
		q.	Advertising
	Costs related to advertising and promotion of products, are charged to selling and marketing expense as incurred.
		r.	Earnings (loss) per share
	Basic earnings (loss) per share are computed by dividing net income or loss applicable to ordinary shareholders by the weighted average number of shares of the Company's ordinary shares outstanding for each period.
Diluted earnings (loss) per share are calculated by dividing net income or loss applicable to ordinary shareholders by the fully-diluted weighted-average number of ordinary shares outstanding during each
period. Potentially dilutive shares are comprised of: (i) incremental ordinary shares issuable upon the exercise of share options, restricted shares or warrants, using the treasury stock method; and (ii) shares issuable upon conversion of preferred shares using the "if-converted" method. Performance-vested share awards are included in the average diluted shares outstanding each period if the performance criteria have been met at the end of the respective periods.
Basic and diluted earnings (loss) per share are presented in conformity with the two-class method for participating securities for the period prior to their conversion upon the Company's initial public offering in October 2013 when all preferred shares were converted into ordinary shares. Under this method the earnings per share for each class of shares (ordinary shares and preferred shares) are calculated assuming 100% of the Company's earnings are distributed as dividends to each class of shares based on their contractual rights. In addition, since preferred shareholders do not participate in losses, for the year ended December 31, 2011 preferred shares are not included in the computation of basic and diluted net loss per share.
	s.	Derivatives
The Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts, and written and purchased currency options). The transactions are designed to hedge the Company's currency exposure.
Derivatives that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of "financial expenses - net" in the consolidated statements of operations and comprehensive income (loss).
For derivatives that qualify for cash-flow hedges, the effective portion of these derivatives' fair value is initially reported as a component of other comprehensive income or loss.
For derivatives that do not qualify for hedge accounting, the cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives are hedging.
	t.	Fair value measurement
The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of bank borrowing also approximates the carrying value since it bears interest at rates close to the prevailing market rates.
The three levels of inputs that may be used to measure fair value are as follows:
Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
Level 3 - Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
	u.	Concentration of credit risks, trade receivables and suppliers.
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and trade receivables. The Company deposits cash and cash equivalents with highly rated financial institutions, mainly Israeli and U.S. banks. Deposits in U.S. banks are federally insured up to $250,000 per account. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.
The Company performs ongoing credit evaluations to estimate the need for maintaining reserves for potential credit losses. An allowance for doubtful accounts is recognized on a specific basis with respect to those amounts that the Company has determined to be doubtful of collection. No allowance for doubtful accounts was recorded in the years ended December 31, 2013, 2012 and 2011.
At December 31, 2013, two customers accounted for more than 10% of gross accounts receivable with balances of $4,172,000 and $3,688,000.
At December 31, 2012, one customer accounted for more than 10% of gross accounts receivable with a balance of $2,440,000.
The Company is dependent on third parties to supply krill meal, an essential raw material for the production of krill oil, which accounted for 53.8% and 49.8% of total net revenues in 2013 and 2012, respectively. The Company currently purchases krill meal pursuant to a memorandum of understanding with the owners of a vessel that harvests Antarctic krill. It also purchases krill meal from several other suppliers, subject to availability. There are a limited number of vessels capable of producing krill meal onboard. In 2013, a distribution company from which the Company previously purchased krill meal declared bankruptcy and, although no material disruption to the krill meal supply occurred and the Company was able to make alternative arrangements with the owner of the vessel, if the Company, for any reason, is no longer able to obtain the krill meal from a supplier on terms reasonable to it, or at all, this would have a material adverse effect on its results of operations and financial condition.
	v.	Recently issued accounting pronouncements
In February 2013, the FASB issued ASU 2013-04, which provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, except for obligations addressed within existing guidance under U.S. generally accepted accounting principles. The update is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2013, with early adoption permitted. The Company believes that the adoption of this standard will not have a material impact on its consolidated financial statements.

INITIAL_PUBLIC_OFFERING_IPO

INITIAL PUBLIC OFFERING ("IPO")	12 Months Ended
	Dec. 31, 2013
INITIAL PUBLIC OFFERING ("IPO")[Abstract]	'
INITIAL PUBLIC OFFERING ("IPO")	'
	NOTE 2 - INITIAL PUBLIC OFFERING ("IPO")
	On October 2, 2013, the Company closed its IPO in the United States with respect to the sale of 5,073,800 ordinary shares. In connection with the IPO, the Company's ordinary shares were listed on the NASDAQ Global Select Market. The IPO price was $14 per share. After deducting the underwriting discount and the offering expenses, the net proceeds to the Company from the offering amounted to $62,838,000. The number of shares offered included the underwriters' option to purchase an additional 661,800 ordinary shares at the IPO price that was exercised in full prior to closing.
	Upon the closing of the IPO, all warrants issued to the Company's former preferred shareholders were exercised for preferred shares, which subsequently converted together with all other outstanding preferred shares into ordinary shares. The following table details the number of ordinary shares outstanding following the closing of the IPO as of October 2, 2013:
		Number of shares
	Ordinary shares outstanding at September 30, 2013		3,167,304
	Ordinary shares issued following the conversion of the preferred shares		12,905,312
	outstanding
	Ordinary shares issued following the exercise of preferred share warrants and subsequent conversion		385,084
	Ordinary shares issued in the IPO (including the underwriters' option to purchase additional shares)		5,073,800
	Total ordinary shares outstanding at October 2, 2013		21,531,500
	In connection with the closing of the IPO and in accordance with their original terms, the vesting period for certain options was accelerated such that options to purchase 262,888 ordinary shares vested and became exercisable upon the closing of the IPO and options to purchase 224,740 ordinary shares will vest and become exercisable no later than one year from the closing of the IPO. Additionally, restricted shares, whose vesting was also subject to the occurrence of a change in control event (i.e. closing of an IPO) will vest according to their vesting schedule, see also Note 10d.
	In addition, following the closing of the IPO, the Company's Board of Directors approved a grant of 9,520 fully vested restricted shares to the Company's current vice-chairman of the board, see also Note 10d.
	Accordingly, the Company recorded $0.9 million of share-based compensation expense in the fourth quarter of 2013 in respect of vested options and restricted shares.
	In addition, the Company recorded $1.0 million of expense in respect of IPO-related bonuses to certain employees. Such bonuses were partly subject to the closing of the IPO ($0.5 million) and partly subject to the Company's market capitalization exceeding an agreed upon level for at least 30 trading days within 24 months following its IPO ($0.5 million). As all conditions were met, the Company recorded the expense in the fourth quarter of 2013.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
PROPERTY, PLANT AND EQUIPMENT [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	NOTE 3 - PROPERTY, PLANT AND EQUIPMENT
	Composition of property and equipment grouped by major classifications is as follows:
			31-Dec
			2013		2012
			U.S. dollars in thousands
	Manufacturing equipment		$	17,993	$	14,365
	Buildings			10,269		8,985
	Laboratory equipment			2,792		2,442
	Land*			951		951
	Furniture, office equipment and computers			1,082		886
	Leasehold improvements			161		161
	Vehicles			18		42
	Advances on account of acquisition of machinery and equipment			119		636
				33,385		28,468
	Less: accumulated depreciation and amortization			7,021		5,504
			$	26,364	$	22,964
		*	Land includes long-term leasehold rights in Israel with useful lives of 98 years.
	Depreciation and amortization expense totaled $1,551,000, $1,422,000 and $1,233,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	As to pledges and guarantees, see Note 11.

JOINT_COLLABORATION_AGREEMENT

JOINT COLLABORATION AGREEMENT	12 Months Ended
	Dec. 31, 2013
JOINT COLLABORATION AGREEMENT[Abstract]	'
JOINT COLLABORATION AGREEMENT	'
	NOTE 4 - JOINT COLLABORATION AGREEMENT
	As described in Note 1, the Company has entered into a joint collaboration agreement with a Swedish vegetable oil company. The joint collaboration agreement's initial term ends on December 31, 2016. Thereafter the agreement will be automatically extended for consecutive periods of three years, unless terminated by a notice of either party at least 12 months prior to its expiration. Under the joint collaboration agreement and two related supply agreements entered into between the parties, the activities of the joint operations are allocated as follows:
	The Company has the responsibility for production of the enzyme, research and development, marketing and business development activities. The Partner has responsibility for the supply chain (purchase and procurement of raw materials, managing stock, delivery and collection). Advanced Lipids operates as a low risk distributor of the joint collaboration. The Company recognizes revenues from its sales to the Partner only upon sale by Advanced Lipids to its customers. As described in Note 1f, the Company accounts for its investment in Advanced Lipids using the equity method of accounting and recognizes its 50% proportionate share of the profit or loss of Advanced Lipids. For the years ended December 31, 2013, 2012 and 2011, sales of the Company through this joint collaboration amounted to $16,666,000, $8,183,000 and $3,533,000, respectively. At December 31, 2013 and 2012, the receivable balance was $5,370,000 and $3,411,000, respectively.
	The Company and the Partner have an ongoing dispute with regard to certain disclosures made by the Company in connection with its IPO, which according to the Partner violated certain non-disclosure obligations in its joint collaboration agreement with the Company. The Company maintains that it has complied with the requirements of the agreement and also requested a consultation in connection with breaches of the agreement that it alleges the Partner has made. The parties are currently engaged in a process to resolve such disputes according to the dispute resolution provisions that are included in the agreement. The Company does not know whether the Partner will pursue any claim and, if it does, the form that such claim might take. The outcome of this dispute and any legal proceedings, if commenced, is inherently uncertain. Any such proceedings could be disruptive to the joint venture's activities and require significant attention from management.

SEGMENT_INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2013
SEGMENT INFORMATION [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 5 - SEGMENT INFORMATION
	The Chief Executive Officer ("CEO") is the Company's chief operating decision-maker ("CODM"). At December 31, 2013, management has determined that there are two operating segments, based on the information reviewed by the CEO for the purposes of allocating resources and assessing performance.
	Nutrition.  This segment develops and manufactures lipid compositions and bioactive ingredients as ingredients for infant formula and dietary supplements, which are tailored to the special needs of the nutrition industry. These ingredients include InFat, a proprietary, clinically-proven infant formula fat ingredient that mimics human breast milk fat to facilitate healthy infant development and premium phospholipids-based bioactive ingredients for nutritional supplements. The best-selling product is krill oil, which provides the anti-aging benefits of Omega-3 fatty acids. Other products are targeted at improving brain health and providing benefits in memory, learning abilities and concentration.
	VAYA Pharma.  This segment develops, manufactures and sells branded lipid-based medical foods for the dietary management of medical disorders and common diseases. This is a research-based, specialty pharmaceutical segment, which currently offers medical foods products for the cardiovascular and neurological markets.
	Through September 30, 2013, the Infant Nutrition and the Bio Active Ingredients operating segments of the Company were aggregated into one reportable segment, Nutrition. These operating segments were aggregated because they shared similar products, manufacturing processes, customers, distribution methods and regulatory environments as well as had similar economic characteristics. Beginning in the fourth quarter of 2013, the operations and management of Infant Nutrition and Bio Active Ingredients segments were consolidated into one operating segment that includes all of the Nutrition products.
	The Nutrition Segment includes the results of Advanced Lipids and other activities performed at the Company level. For accounting purposes, the results of Advanced Lipids are recorded using the equity method
	of accounting. For management purposes, the results of Advanced Lipids are analyzed based on proportionate consolidation, which represents the Company's share (50%) of the gross results of Advanced Lipids.
	The CEO assesses the performance based on a measure of "Adjusted EBITDA" (earnings before financial expenses, tax, depreciation and amortization and excluding share-based compensation expense and other unusual income or expenses). This measure is also used in the calculation of the financial covenants as described in Note 9f.
	The measure of assets has not been disclosed for each segment as it is not regularly provided to the CODM.
	Segment data for the year ended December 31, 2013 is as follows:
			Nutrition		Vaya			Total		Elimination**			Consolidated
					Pharma
			U.S. dollars in thousands
	Net revenues from external customers		$	76,167	$	4,444		$	80,611	$	(15,636	)	$	64,975
	Cost of revenues*			45,804		1,255			47,059		(14,981	)		32,078
	Gross profit*			30,363		3,189			33,552		(655	)		32,897
	Operating expenses*			13,009		6,020			19,029					19,029
	Depreciation and amortization			1,415		136
	Adjusted EBITDA		$	18,769	$	(2,695	)
	IPO related bonus													1,000
	Share-based compensation expense													1,109
	Operating Income												$	11,759
	Financial expenses - net													531
	Income before taxes on income												$	11,228
		*	Including depreciation and amortization but excluding share-based compensation expense and IPO-related bonus.
		**	Representing the change from proportionate consolidation to the equity method of accounting.
	Segment data for the year ended December 31, 2012 is as follows:
			Nutrition		Vaya Pharma			Total		Elimination**			Consolidated
			U.S. dollars in thousands
	Net revenues from external customers		$	44,380	$	1,832		$	46,212	$	(8,345	)	$	37,867
	Cost of revenues*			27,297		588			27,885		(8,087	)		19,798
	Gross profit*			17,083		1,244			18,327		(258	)		18,069
	Operating expenses*			7,850		4,637			12,487					12,487
	Depreciation and amortization			1,304		118
	Adjusted EBITDA		$	10,537	$	(3,275	)
	Share-based compensation expense													267
	Operating Income													5,315
	Financial expenses - net													539
	Income before taxes on income												$	4,776
		*	Including depreciation and amortization but excluding share-based compensation expense.
		**	Representing the change from proportionate consolidation to the equity method of accounting.
	Segment data for the year ended December 31, 2011 is as follows:
			Nutrition		Vaya Pharma			Total		Elimination**			Consolidated
			U.S. dollars in thousands
	Net revenues from external customers		$	27,266	$	739		$	28,005	$	(4,986	)	$	23,019
	Cost of revenues*			17,955		447			18,402		(4,942	)		13,460
	Gross profit*			9,311		292			9,603		(44	)		9,559
	Operating expenses*			7,735		1,828			9,563					9,563
	Depreciation and amortization			1,168		65
	Adjusted EBITDA		$	2,744	$	(1,471	)
	Share-based compensation expense													343
	Operating loss													(347	)
	Financial expenses- net													416
	Loss before taxes on income												$	(763	)
		*	Including depreciation and amortization but excluding share-based compensation expense.
		**	Representing the change from proportionate consolidation to the equity method of accounting.
		b.	Entity Wide Information:
		1)	Net sales by geographic location were as follows:
			Year ended December 31
			2013		2012			2011
			U.S. dollars in thousands
	North America		$	35,458	$	17,487		$	14,394
	Europe			10,382		6,828			3,557
Australia			10,811		11,763			1,474
Asia			7,735		1,497			3,094
Israel			589		292			500
Total revenue		$	64,975	$	37,867		$	23,019
	2)	Substantially all of the Company's long lived assets are located in Israel.
	3)	Sales of three products out of the Nutrition Segment, which exceed 10% of total sales, are as follows:
		Year ended December 31
		2013		2012			2011
		U.S. dollars in thousands
Krill oil		$	34,926	$	18,841		$	9,701
InFat		$	16,666	$	8,183		$	3,533
Sharp PS		$	5,248	$	4,978		$	3,589
	4)	Net revenue from principal customers - Net revenues from single customers out of the Nutrition Segment that exceed 10% of total net revenue in the relevant year:
		Year ended December 31
		2013		2012			2011
U.S. dollars in thousands
Customer A		$	7,692	$	9,426		$	1,179
Customer B		$	1,301	$	2,130		$	2,801
Customer C		$	2,329	$	2,586		$	2,626
Customer D		$	9,833	$	595		$	-

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
INVENTORIES [Abstract]	'
INVENTORIES	'
	NOTE 6 - INVENTORIES:
		31-Dec
		2013		2012
		U.S. dollars in thousands
	Raw materials and supplies	$	6,550	$	4,663
	In-process inventories	$	3,790		2,360
	Finished goods	$	1,603		2,336
		$	11,943	$	9,359

BORROWINGS

BORROWINGS	12 Months Ended
	Dec. 31, 2013
BORROWINGS [Abstract]	'
BORROWINGS	'
	NOTE 7 - BORROWINGS
	In September 2009, the Company entered into a financing agreement (the "Financing Agreement") with a bank (the "Bank"), which amounted to $10.6 million and was comprised of the following:
		a.	Long-term loans
	The loans are due for repayment as follows:
		1)	A loan of $1.4 million which bore annual interest rate of LIBOR+3.6% and was repaid in 24 monthly installments starting January 2010.
		2)	A loan of $5.6 million which was due in one installment on October 2011 unless extended, upon meeting certain financial and other covenants determined in the Financing Agreement.
	In accordance with the original terms, the loan was extended for an additional 8 years (96 monthly installments starting January 2012 - $700,000 annually). The loan bears a floating rate of one-month LIBOR plus 5.05%.
	In February 2010, the Company entered into an interest rate swap agreement with a third party in respect to its $5.6 million principal amount long-term loan. The purpose of the transaction was to change the interest from floating rate to fixed rate. As a result of this agreement, the Company pays, starting March 2011 through February 2015, an effective interest rate of 8.37% on the $5.6 million principal amount, instead of the original floating rate of one-month LIBOR plus 5.05%. The above transaction qualified for cash flows hedge accounting.
	In December 2013, the Company notified the Bank that it was exercising its right for early repayment of the entire loan. Accordingly, the loan was classified as a current maturity and the interest rate swap transaction no longer qualified for cash flows hedge accounting. As a result, the Company recorded $282,000 of financial expenses in the fourth quarter of 2013, representing the fair value of the cash flow hedge transaction mentioned above and the early repayment fee. The loan was repaid in full at January 31, 2014.
		b.	Short-term credit line for financing of working capital
	As part of the Financing Agreement, the Company also received a short-term credit line from the Bank of up to $3.6 million. During 2011, the credit line was increased to $5.6 million. In May 2012, the Company signed an amendment to the short-term credit line agreement. The credit line was increased to an amount, which is the lower of $7.6 million or 20% of the consolidated net revenues for the last reported four quarters. The short-term credit line expired on December 31, 2013.
	As to pledges, charges, liens and guarantees relating to all financing agreements, see Note 11.

EMPLOYEE_RIGHTS_UPON_RETIREMEN

EMPLOYEE RIGHTS UPON RETIREMENT	12 Months Ended
	Dec. 31, 2013
EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]	'
EMPLOYEE RIGHTS UPON RETIREMENT	'
	NOTE 8 - EMPLOYEE RIGHTS UPON RETIREMENT
	The Company is required to make severance payments with respect to its Israeli employees upon dismissal of an employee or upon termination of employment in certain circumstances.
	In accordance with the current employment agreements with most of its Israeli employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's retirement benefit obligation. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company's consolidated balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plan").
	With regard to the employees without a Contribution Plan, the liability is funded in part by the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. These policies are the Company's assets. The severance payment liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year of employment) is recorded on the Company's balance sheets under "retirement benefits obligation". The liability is recorded as if it was payable at each balance sheet date on an undiscounted basis. In the years ended December 31, 2013, 2012 and 2011, the Company deposited $156,000, $139,000 and $158,000, respectively, with insurance companies and pension funds in connection with its severance payment obligations.
	The amounts of severance payment expenses were $506,000, $284,000 and $317,000 for the years ended December 31, 2013, 2012 and 2011, respectively, of which $230,000, $145,000 and $120,000 in the years ended December 31, 2013, 2012 and 2011, respectively, were in respect of the Contribution Plan and funded accordingly. Gains (losses) on the amounts funded in insurance companies and pension funds, in respect of retirement benefit obligation totaled $154,000, $74,000 and $(58,000) for the years ended December 31, 2013, 2012 and 2011, respectively.
	The Company expects to contribute approximately $530,000 in the year ending December 31, 2014 to insurance companies in connection with its severance liabilities for its operations for that year, $365,000 of which will be contributed to a Contribution Plan.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 9 - COMMITMENTS AND CONTINGENCIES:
		a.	Operating leases
	As of December 31, 2013, minimum future rentals under operating leases of office space, machinery and equipment and vehicles for periods in excess of one year amounted to $897,000 and were to be paid as follows: 2014 - $419,000; 2015 - $277,000; 2016 - $192,000; 2017 - $9,000. The lease expenses in each of the years ended December 31, 2013, 2012 and 2011 were $452,000, $355,000 and $276,000, respectively.
		b.	Marketing and distribution agreements
	The Company has entered into marketing and distribution agreements with commercial entities with respect to its products. Under the terms of the agreements, the distributors have received rights to distribute the products in a defined territory and for various periods.
		c.	Joint Venture ("JV") agreement
	On December 4, 2013, the Company signed a JV agreement with Polar Omega A/S, a Danish company specializing in the production of marine phospholipids from sustainable fish sources for the commercialization of Omega PCTM, a new premium fish based omega-3 product. Under the agreement, Enzymotec will be responsible for global sales and marketing, research and development, and for the intellectual property regarding Omega PCTM. Polar Omega will be responsible for supply chain, including sourcing of raw materials and manufacturing Omega PCTM.
		d.	Royalties:
		1)	The Company is committed to pay royalties to the Office of the Chief Scientist of the Israeli Ministry of Economy (the "Chief Scientist"); the royalties are computed based on the Company's net revenues arising from know-how in the research and development in which the Chief Scientist participated by way of grants. Under the terms of the Company's funding from the Chief Scientist, royalties of 3% - 5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked with the addition of annual interest at LIBOR rate). At the time the grants were received, successful development of the related projects was not assured. In the case of failure of a project that was partly financed by royalty-bearing Government grants, the Company is not obligated to pay any such royalties to the Israeli Government.
	At December 31, 2013, the maximum royalty amount payable (including interest) by the Company is approximately $3 million.
		2)	In 2001, the Company and a third party (the U.S. Partner) entered into an agreement for the development, manufacture and supply of a new product. The development of this product was funded by BIRD - Israel-U.S. Binational Industrial Research and Development Foundation (the "BIRD Foundation"). The Company is committed to pay royalties to the BIRD Foundation which are computed based on the Company's net revenues from sale of products in the development of which the BIRD Foundation participated.
	The U.S. Partner has terminated the research project and the BIRD Foundation gave its consent to the termination as above. Therefore, the Company is not expected to derive any revenues from the said research; however, in case such revenues shall arise to the Company, the maximum royalty amount payable by the Company is $ 370,000 as of December 31, 2013.
		3)	Royalty expenses for the years ended December 31, 2013, 2012 and 2011 were recorded in cost of revenues and amounted to $101,000, $40,000 and $416,000, respectively.
		e.	Litigation:
		1)	The Company is party to a number of actions initiated by Neptune Technologies & Bioressources Inc., ("Neptune"), in which Neptune has claimed that the Company's krill oil products infringe certain of its patents, namely U.S. Patent Nos. 8,030,348, 8,278,351 and 8,383,675, (the "348 patent", the "351 patent" and the "675 patent", respectively). The complaints with respect to each of these patents were filed against the Company and certain other parties in the United States District Court for the District of Delaware, (the "District Court"), in October 2011, October 2012 and February 2013, respectively. In each of the complaints, Neptune seeks both permanent injunctions
			prohibiting the Company from making or selling the allegedly infringing products and an unspecified amount of monetary damages against the Company and the other defendants.
	Additionally, in April 2013, the Company received a notice of an investigation by the United States International Trade Commission, ("ITC"), regarding complaints filed before the ITC by Neptune and its subsidiary, Acasi Pharma Inc. Neptune and its subsidiaries instituted these complaints against the Company and certain of Neptune's other principal competitors in the United States alleging a violation of section 337 of the Tariff Act of 1930 by reason of alleged infringement of the 351 patent and the 675 patent.
	A hearing was scheduled for December 17, 2013, but prior to the date of the hearing, the Company entered into a non-binding term sheet with Neptune for the settlement of the claims. As a result of the entry into the term sheet, the ITC proceeding was stayed through January 15, 2014 pending the Company's agreement with Neptune on definitive terms of the settlement and entry into a binding settlement agreement. The stay was then extended until February 5, 2014. The parties were not able to finalize the settlement agreement during this time. On February 11, 2014, the parties informed the ITC Administrative Law Judge that they would request mediation and would be filing a motion for a further 60-day stay of the ITC proceedings. The Company does not know whether this matter will be settled through mediation or otherwise or whether the ITC proceedings will be re-commenced.
	Each of the District Court patent proceedings has been stayed pending resolution of the ITC proceeding as described below:
	348 Patent - In February 2012, the District Court stayed the 348 patent litigation against the Company pending the issuance of an Action Closing Prosecution which is a preliminary decision issued by the United States Patent and Trademark Office ("USPTO") during certain types of re-examinations after considering the issues concerning patentability a second or subsequent time, in an inter partes re-examination proceeding by the USPTO, of the 348 patent. This inter partes re-examination was initiated by krill oil producer Aker BioMarine ASA ("Aker"). In May 2013, the USPTO issued an "Action Closing Prosecution" that rejected all of the claims in the 348 patent. However, this action is not final, and Neptune filed written comments in response, which were responded to by Aker. The USPTO has not yet acted in response to Neptune and Aker's submissions. Moreover, even if a final decision is made adversely to Neptune, Neptune may have the opportunity to file an appeal. Because of the issuance of the Action Closing Prosecution, the District Court's stay has expired. However, on July 31, 2013, the District Court stayed the 348 patent litigation pending a decision in the ITC proceeding described above.
	351 Patent - In May 2013, the District Court stayed Neptune's litigation against the Company involving the 351 patent pending the results of the ITC proceeding described above. In December 2012, the USPTO granted a request by Aker for ex parte re-examination of the 351 patent. In January 2014, the USPTO issued a Non-Final Office Action rejecting all the claims of the 351 patent. In addition, in October 2013, Aker filed a petition with the Patent Trial Appeal Board ("PTAB") of the USPTO for inter partes review of the 351 Patent. That petition has not yet been decided.
	675 Patent - Neptune has agreed to stay the 675 patent litigation pending a decision in the ITC proceeding described above. In November 2013, Aker filed a petition with the PTAB for inter partes review of the 675 Patent. However, that inter partes review petition was terminated based on a joint motion by Aker and Neptune pursuant to a settlement agreement between the parties.
	Management believes that there are several different possible outcomes of the litigations and proceedings in respect of the above three Neptune patents. The USPTO could confirm Neptune's patent claims in respect of the 348 patent and/or the 351 patent or cancel them completely, or reject
	some and confirm others of these claims, or Neptune could amend its claims in some way to put them in a position for allowance. In addition, if the settlement is not finalized, the ITC could issue a decision preventing the Company from importing krill oil products into the United States; find that the 351 patent and/or the 675 patent are invalid; or decide that either the 351 patent or the 675 patent or both are not infringed by krill oil products imported into the United States. It is not certain whether any of the litigations involving the 351 patent and 675 patent will continue at all or to the same extent, or how strong Neptune's claims will be after the conclusion of the USPTO re-examination(s) of the 348 patent and/or the 351 patent, inter partes review of the 351 patent or the ITC proceeding. Moreover, it is unclear whether the patent claims asserted against the Company in these litigations will differ from the ones that are currently in the applicable patents.
	Management believes that the Company has meritorious defenses to the patent claims as currently asserted against the Company in the patent litigations, and, absent settlement, it intends to vigorously contest the complaints made by Neptune. If any claim of these patents is found to be infringed, valid and enforceable by the District Court, the District Court could award damages against us, including monetary damages in the form of lost profits or a reasonable royalty, as determined by the District Court (with the possibility of interest and fees). Treble damages may also be awarded if the applicable requirements are found. Calculating the measure of lost profits or a reasonable royalty is complex and would depend in part on aspects of Neptune's business that are not known to the Company. In addition, the Company has agreed to indemnify and be financially responsible for any damages awarded against certain of its customers resulting from the purchase, importation, sale, use or offer to sell of the Company's products in the event such products are found to infringe certain of Neptune's patent rights. An injunction by the District Court or an exclusion order by the ITC could also be issued against the Company, either of which could prevent the Company from selling the allegedly infringing products in the United States, a significant market for the Company's krill oil products.
	The District Court or ITC could also order other actions that could impose additional costs and expenses upon the Company. Moreover, the Company could suffer significant reputational harm from any adverse ruling in these actions, which could significantly affect its market value, and such harms and negative effects could also occur from the mere expectation that an adverse ruling could be issued. Management believes an estimate of the likelihood that the Company might incur financial loss as a result of the litigation with Neptune, as required by ASC 450-20-50-4, cannot be made at this time, and accordingly the Company has not included any provision in its consolidated financial statements for these claims.
		2)	In March 2013, a claim was filed against the Company in the Haifa District Court, Israel, seeking a finder's fee in connection with funds invested in the Company by one of its investors (the "Claim").
	The Claim is based upon an agreement, dated March 2000, between the Company and the plaintiff, pursuant to which the Company agreed to pay him a finder's fee, should he introduce the Company to an investor who would invest an amount in excess of $500,000 in the Company. In previous litigation between the Company and the plaintiff concerning this agreement, the plaintiff claimed to have been entitled to a finder's fee in respect of investment made by an investor in the Company, although the investment materialized more than a year later. This previous claim was adjudicated in his favor and the Company paid him a fee of $75,000.
	In the present Claim, the plaintiff alleges that he is entitled to an additional finder's fee in the amount of NIS 6.2 million (approximately $1.8 million) in connection with the multiple investments made by the same investor over the past 11 years. Management believes, based on the language of the agreement, as well as various other documents that the demonstrable intention of the parties was that he would receive a fee only for the initial investment, and not in respect of any later
	investments, and it intends to defend this Claim vigorously. Accordingly, the Company has not included any provision in its accounts for this Claim.
	In April 2013, the Company filed a motion to be permitted to defend. This motion was granted in September 2013. The parties are currently engaged in document discovery.
		f.	Financial and other Covenants
	As part of the Financing Agreement (see Note 7), the Company committed to meet certain financial and other covenants determined in the Financing Agreement. The major financial covenants are:
		1)	Shareholders' equity must exceed $20 million.
		2)	Shareholders' equity must exceed 45% of total assets.
		3)	Adjusted EBITDA, as defined in the Financing Agreement, must exceed $1.5 million.
		4)	The ratio between Net Debt (defined as all liabilities to banks and financial institutions minus the company's cash and cash equivalents) and Adjusted EBITDA (as defined in the Financing Agreement) must be below 5 in 2012 and below 4 in 2013 and thereafter.
	Should the Company fail to meet the agreed covenants, the Bank will be able to demand immediate repayment of all outstanding balances and cancel the short-term credit line.
	As of December 31, 2013, the Company was in compliance with all covenants. Following the early repayment of the long-term loan at January 31, 2014 (see Note 7), such covenants will be removed.
		g.	As to pledges and guarantees, see Note 11.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
SHAREHOLDERS' EQUITY [Abstract]	'
SHAREHOLDERS' EQUITY	'
	NOTE 10 - SHAREHOLDERS' EQUITY:
		a.	Share capital:
		1)	On September 2, 2013, the Company's shareholders approved an increase in its authorized share capital to an aggregate of NIS 1 million divided into 100 million ordinary shares. On September 12, 2013, the Company effected a bonus share distribution under which: (i) 67 bonus shares were issued for each share outstanding prior to such distribution; and (ii) the conversion rate for each preferred share, option and warrant was adjusted to reflect such bonus share distribution.
		2)	Ordinary shares
	The ordinary shares confer upon their holders voting rights and the right to participate in shareholders' meetings (the holders of shares of NIS 0.01 par values are entitled to one vote per share), the right to receive profits and the right to share in excess assets upon liquidation of the Company.
		3)	Preferred shares
	Until the closing of the IPO (see Note 2), the A, B, B1 and B2 preferred shares conferred upon their holders voting rights similar to the ordinary shares and the right to participate in dividends in priority to holders of ordinary shares. In addition, the holders of preferred shares had additional preferential rights including liquidation, conversion and other rights as defined. Upon the closing of the IPO, all outstanding preferred shares were converted into ordinary shares and accordingly the former preferred shareholders are no longer entitled to such preferential rights.
		4)	Share Purchase Agreement ("SPA")
	In September 2011, the Company signed an SPA with certain of its shareholders. Following this SPA and certain amendments signed by the Company, certain shareholders and a new investor (the "New
	Investor") undertook to invest in the Company $11.3 million (the "Investment Amount") in exchange for Series B2 Preferred shares NIS 0.01 par value and at a price per share equal to $5.34.
	The Investment Amount was paid in two equal installments, as follows: (i) upon signing the SPA (ii) the remaining portion was to be transferred and paid to the Company from time to time but no later than December 31, 2012. Through March 31, 2012, the first installment ($5.65 million) was fully paid. In addition, the New Investor received an option to invest, in accordance with the same terms and conditions of the SPA, an additional amount of $1.2 million (the "Additional Amount"), which option was exercisable at the same price per share by him not later than December 31, 2012 (potentially increasing the amount of this financial round to $12.5 million). In December 2012, the New Investor exercised its option to invest the Additional Amount of $1.2 million. On November 20, 2012, the Company's Board of Directors approved the extension of the payment of the second installment (including the Additional Amount) through January 15, 2013. Through January 15, 2013, the second installment, including the Additional Amount, was fully paid.
	In addition, the Company issued to each of the investors warrants to purchase additional Series B2 Preferred shares amounting to 20% of the number of Series B2 Preferred shares purchased by them as part of the investment round.
	Such warrants could be exercised, in whole or in part, (A) for cash, at any time but prior to the earlier to occur of: (i) the closing of an IPO (ii) the closing of a Deemed Liquidation Event; or (iii) the fifth anniversary of the Closing, as defined; or (B) on a cashless basis immediately prior to an IPO or a Deemed Liquidation.
	Upon the closing of the IPO (see Note 2), all warrants issued to the Company's former preferred shareholders were exercised for preferred shares on a cashless and non-cashless basis, in consideration of $1.3 million, with respect to the non-cashless exercise only. The underlying preferred shares subsequently converted into ordinary shares.
		b.	Option plans
	In 2001, 2003 and 2013 the Company's Board of Directors approved option plans for employees, directors and service providers (the "Plans"). Through December 31, 2013, the Company granted as part of the Plans 4,092,988 options and restricted shares (see d. below) to employees, directors and service providers. Each option is exercisable into one ordinary share of NIS 0.01 par value. At December 31, 2013, 466,684 shares were available for issuance upon grants of options or restricted shares under the Plans.
	From the effective date of grant, options generally vest over a 4-year period 25% each year. Immediately upon exercise, the ordinary shares issued will have the same rights as all other ordinary shares. In general, any option not exercised within 10 years from the grant date or within three months from the termination of employment) will expire, unless extended by the Board of Directors.
	The Plans with respect to Israeli employees are intended to be governed by the terms stipulated by Section 102 of the Israeli Income Tax Ordinance. In accordance with the capital gain track chosen by the Company and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the Plan - with the exception of the work-income benefit component, if any, determined on the grant date. Options granted to employees from other countries are subject to similar terms with certain changes required for local regulations.
	The fair value of options granted during the years ended December 31, 2013, 2012 and 2011 was $2.02, $0.23 and $0.33, respectively.
	The fair value of each option granted is estimated on the date of grant using the binomial option-pricing model, with the following assumptions:
			2013			2012			2011
	Dividend yield			0	%		0	%		0	%
	Expected volatility			67	%		60	%		77	%
	Risk-free interest rate			1.8	%		2.2	%		1.8	%
	Contractual term			10 years			10 years			10 years
	Early exercise multiple			215% - 246	%		218% -  229	%		218% - 229	%
	The expected volatility is based on the historical volatility of comparable companies. The risk-free interest rate assumption is derived from the interest curve for U.S. government bonds for periods corresponding to the life term of the option on the grant date. The early exercise multiple was based on data of comparable companies.
	The total unrecognized compensation cost of employee options (not including compensation cost in respect of restricted shares, see d. below) at December 31, 2013 is $180,000, which is expected to be recognized over a weighted average period of 1.38 years.
	A summary of share option plans (excluding restricted shares information, see d. below), and related information, under all of the Company's equity incentive plans for the years ended December 31, 2013, 2012 and 2011 are as follows:
	Options granted to employees, directors and service providers:
			Year ended December 31
			2013						2012					2011
			Number of shares upon exercise			Weighted average exercise price*			Number of shares upon exercise			Weighted average exercise price*		Number of shares upon exercise			Weighted average
																	exercise price*
	Outstanding at the beginning of the year			1,866,940			2.13			1,789,760			2.08		1,576,648			1.92
	Granted			174,420			6.02			168,980			3.12		282,200			2.88
	Exercised			(47,940	)		0.15								(51,272	)		0.94
	Forfeited			(25,636	)		3.12			(91,800	)		3.12		(17,816	)		3.04
	Outstanding at the end of the year			1,967,784			2.51			1,866,940			2.13		1,789,760			2.08
	Exercisable at the end of the year			1,747,532			2.29			1,335,112			1.74		1,067,668			1.45
		*	In dollars per share.
	At December 31, 2013, there were 56,100 options outstanding with an average exercise price of $1.73 and average remaining contractual life of 3.80 years, which were granted to service providers. At December 31, 2013, all of these options were exercisable.
	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2013:
	Options outstanding											Options exercisable
	Exercise prices*		Shares upon exercise of options outstanding at end of year			Weighted average remaining contractual life			Aggregate intrinsic value			Shares upon exercise of options outstanding at end of year		Weighted average remaining contractual life			Aggregate intrinsic value (U.S. dollars in thousands)
									(U.S. dollars in thousands)
	0.0001			285,600			1.78			7,714			285,600		1.78			7,714
	0.001			27,200			0.96			735			27,200		0.96			735
	1.47			408,000			4.93			10,420			408,000		4.93			10420
	1.62			40,800			4.62			1,036			40,800		4.62			1,036
	3.12			1,031,764			6.98			24,649			870,536		6.97			20,797
	5.34			160,820			9.27			3,485			115,396		9.27			2,501
	14			13,600			9.76			177
				1,967,784			5.87			48,216			1,747,532		5.65			43,203
		*	In dollars per share
	The aggregate intrinsic value in the above table represents the total pre-tax intrinsic value, based on the Company's closing share price of $27.01 on December 31, 2013, less the exercise price. This represents the potential amount receivable by the option holders had all option holders exercised their options as of such date.
	The following table illustrates the effect of share-based compensation expense on the consolidated statement of operations and comprehensive income (loss):
			Year ended December 31
			2013			2012			2011
			U.S. dollars in thousands
	Cost of revenues		$	32		$	17		$	8
	Research and development expenses - net			56			60			72
	Selling and marketing expenses			77			40			84
General and administrative expenses			944			150			179
		$	1,109		$	267		$	343
	c.	Accumulated other comprehensive loss:
		31-Dec
		2013			2012
		U.S. dollars in thousands
Currency translation adjustment		$	25		$	14
Unrealized loss from cash flow hedge*			(90	)		(261	)
		$	(65	)	$	(247	)
	*	During 2013, an amount of $261,000 in respect of unrealized loss from cash flow hedge was reclassified from accumulated other comprehensive loss into financial expenses.
	d.	Restricted shares
In August 2013, the Company's Board of Directors approved a grant of 156,060 restricted shares to the current chairman of the Board of Directors. The restricted shares are subject to vesting over four years commencing on March 31, 2013 and to other vesting milestones as follows: (i) the vesting of 104,040
restricted shares is subject to the occurrence of a change of control event, as defined; and (ii) the vesting of 52,020 restricted shares is subject to: (a) the occurrence of a change of control event, as defined and (b) the achievement of a market cap milestone, as defined. Following the closing of the IPO, the change in control event occurred and accordingly, the 104,040 restricted shares will vest according to their vesting schedule. In addition, the market cap milestone was met after year-end and the 52,020 restricted shares will vest according to their vesting schedule. The fair value of restricted shares is estimated based on the market value of the Company's stock on the date of award. The Company recorded an expense of $377,000 in the fourth quarter of 2013 in respect of such restricted shares. The total unrecognized compensation expense in respect of such restricted shares is $1,338,000, which is expected to be recognized over a period of 3.25 years.
In November 2013, in connection with the closing of the IPO, the Company's Board of Directors approved a grant of 9,520 fully vested restricted shares to the current vice chairman of the Board of Directors. The Company recorded an expense of $294,000 in the fourth quarter of 2013 in respect of such restricted shares. Such shares were issued in January 2014.

PLEDGES_AND_GUARANTEES

PLEDGES AND GUARANTEES	12 Months Ended
	Dec. 31, 2013
PLEDGES AND GUARANTEES [Abstract]	'
PLEDGES AND GUARANTEES	'
	NOTE 11 - PLEDGES AND GUARANTEES:
		a.	In connection with the Financing Agreement mentioned in Note 7, the Company registered floating charges in favor of the Bank on all of its assets. The Company is in the process of removing such charges, following the early repayment of the long-term loan at January 31, 2014 (see Note 7). The Company also registered fixed liens on its land, property, plant and equipment and on its shares in Enzymotec Inc. (its wholly owned U.S. subsidiary).
		b.	As to indemnification provided to several customers and distributors in connection with litigation, see Note 9.

TAXES_ON_INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2013
TAXES ON INCOME [Abstract]	'
TAXES ON INCOME	'
	NOTE 12 - TAXES ON INCOME:
		a.	Enzymotec Ltd.
	The Company is taxed according to Israeli tax laws:
		1)	Measurement of results for tax purposes
	As explained in Note 1d, the dollar is the functional currency of the Company, and the Company's consolidated financial statements are presented in dollars. The difference between the changes in the Israeli shekel (NIS) and the exchange rate of the dollar, both on an annual and a cumulative basis causes a difference between taxable income and income reflected in these consolidated financial statements.
	ASC 740-10-25 prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are remeasured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.
		2)	Tax rates
	The income of the Company (other than income from "Approved Enterprise" or "Benefited Enterprise", see 3. below) is taxed at the regular corporate tax rate. The regular corporate tax rate in Israel in 2011 was 24%. On December 6, 2011, the "Tax Burden Distribution Law" Legislation Amendments (2011) was published. Under this law, the previously approved gradual decrease in corporate tax was discontinued and the corporate tax rate was increased to 25% as from 2012 and thereafter. On August 5, 2013, the Law for Change of National Priorities (Legislative Amendments
	for Achieving the Budgetary Goals for 2013 - 2014), 2013 was published. Under this law, the corporate tax rate was raised to 26.5% beginning in 2014 and thereafter.
		3)	Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the "Investment Law")
	Under the Investment Law, including Amendment No. 60 to the Investment Law that was published in April 2005, by virtue of the Approved Enterprise or Benefited Enterprise status granted to certain of its production facilities the Company is entitled to various tax benefits.
	The main benefit arising from such status is the reduction in tax rates on income derived from an Approved Enterprise. Income derived from Approved or Benefited Enterprises is tax exempt for a period of up to ten years period of benefits. The period of tax benefits, as described above, is subject to limitations of the earlier of 12 years from the commencement of production, or 14 years from the date of approval. As of December 31, 2013, the period of benefits has not yet commenced.
	In the event of distribution of cash dividends from income which was tax exempt as above, the amount distributed will be subject to the tax rate it was exempted from.
	The Company is entitled to claim accelerated depreciation in respect of equipment used by the approved enterprises during five tax years.
	Entitlement to the above benefits is conditioned upon the Company fulfilling the conditions stipulated by the Approved Enterprise Law and regulations published thereunder, and in the certificate of approval for the specific investments in Approved Enterprises. In the event of failure to comply with these conditions, the benefits may be canceled and the Company may be required to refund the amount of the benefits, in whole or in part, with the addition of linkage differences to the Israeli consumer price index and interest.
		4)	Amendment of the Investment Law
	The Investment Law was amended as part of the Economic Policy Law for the years 2011 - 2012 (the "Amendment"), which became effective on January 1, 2011.
	The Amendment sets alternative benefit tracks to the ones currently in place under the provisions of the Investment Law, including a reduced corporate tax rate for companies located in national development zone A of 10% in 2011 - 2012, 7% in 2013 - 2014 and 6% at 2015 and thereafter.
	The benefits are granted to companies that qualify under criteria set forth in the Investment Law; for the most part, those criteria are similar to the criteria that have existed in the Investment Law prior to its amendment and the benefit period is unlimited in time.
	Under the transitional provisions of the Investment Law, a company is allowed to continue to enjoy the tax benefits available under the Investment Law prior to its amendment until the end of the period of benefits, as defined in the Investment Law. In each year during the period of benefits of its Approved or Benefitted Enterprises, the Company will be able to opt for application of the Amendment, thereby making available to itself the tax rates as above. The Company's election to apply the Amendment is irrevocable.
	As of December 31, 2013, the Company's management decided not to adopt the application of the Amendment.
		5)	Losses for tax purposes, carried forward to future years
	Carryforward tax losses of the Company at December 31, 2013, approximated $12 million.
		b.	Non-Israeli Subsidiaries
	Subsidiaries that are incorporated outside of Israel are assessed for tax under the tax laws in their countries of residence. The principal tax rates (Federal and State) applicable to the subsidiaries incorporated in the U.S. is approximately 40%.
		c.	Tax assessments
	The Company and its subsidiaries have not been assessed since incorporation. In accordance with the Israeli Income Tax Ordinance, tax assessments of the Company through tax year 2007 are considered final.
		d.	Income (loss) before income taxes is composed of the following:
			Year ended December 31
			2013			2012			2011
			U.S. dollars In thousands
	Israel		$	10,414		$	4,360		$	(1,036	)
	Non-Israeli Subsidiaries			814			416			273
			$	11,228		$	4,776		$	(763	)
		e.	Taxes on income - current -
	non-Israeli Subsidiaries		$	324		$	180		$	137
		f.	Uncertain tax positions
	As of December 31, 2013 and 2012, the Company had not accrued a provision for uncertain tax positions.
		g.	Deferred income taxes
	Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. Since the Company is entitled to a tax exemption for a period of ten years, the tax rate used in computation of deferred taxes on its carry forward losses and timing differences is zero.
		h.	Reconciliation of theoretical tax expense to actual tax expense:
			Year ended December 31
			2013			2012			2011
			U.S. dollars in thousands
	Income (loss) before taxes on income		$	11,228		$	4,776		$	(763	)
	Theoretical tax expenses (benefit) at the statutory rate (2013 and 2012 - 25%; 2011 - 24%)			2,807			1,194			(183	)
	Increase (decrease) in taxes on income due to:
	Computation of deferred taxes at a rate, which is different than statutory rate			(2,033	)		(1,157	)		166
	Difference between income reported for tax purposes and income for financial reporting			(754	)
	purposes - mainly dollar - NIS differences
	Non-deductible expenses - mainly share-based compensation expense			183			74			89
	Different effective tax rates applicable to the subsidiaries			121			69			65
			$	324		$	180		$	137

SUPPLEMENTARY_FINANCIAL_STATEM

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2013
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]	'
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	'
	NOTE 13 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
		a.	Accounts receivable - other:
			31-Dec
			2013			2012
			U.S. dollars in thousands
	Advance to supplier		$	1,153		$	1,695
	Institutions			1,065			1,024
	Chief Scientist			77			153
	Fair value of derivatives			1			251
	Prepaid expenses and sundry			442			234
			$	2,738		$	3,357
		b.	Accounts payable and accruals - other:
	Employees and payroll related institutions		$	2,470		$	1,515
	Provision for vacation and recreation pay			426			373
	Royalties payable			57			23
	Fair value of derivatives			222			261
	Accrued expenses and sundry			3,203			910
			$	6,378		$	3,082
		c.	Research and development expenses - net:
			Year ended December 31
			2013			2012			2011
			U.S. dollars in thousands
	Total expenses		$	6,144		$	4,876		$	4,426
	Less - participation and grants			197			265			566
			$	5,947		$	4,611		$	3,860
		d.	Finance expenses - net:
	Interest expenses and other bank charges		$	(595	)	$	(657	)	$	(590	)
	Interest income			50
	Foreign exchange gain (losses) - net			(82	)		(102	)		22
	Gain (losses) in respect of derivatives - net			96			220			152
			$	(531	)	$	(539	)	$	(416	)

FAIR_VALUE_MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 14 - FAIR VALUE MEASUREMENT
	Financial items carried at fair value as of December 31, 2013 and December 31, 2012 are classified in the tables below in one of the three categories described in Note 1s:
			31-Dec-13
			U.S. dollars in thousands
			Level 1		Level 2
	Cash and cash equivalents - cash deposits and other		$	74,430
	Derivatives:
	Interest rate swap (liabilities)					($132	)
	Forward contracts (liabilities)					(90	)
	Forward contracts and currency options (assets)					1
			$	74,430	$	(221	)
			31-Dec-12
			U.S. dollars in thousands
			Level 1		Level 2
	Cash and cash equivalents - cash deposits and other		$	2,729
	Derivatives:
	Interest rate swap (liabilities)				$	(261	)
	Forward contracts and currency options (assets)					251
			$	2,729	$	(10	)
		a.	Foreign exchange risk management
	The Company enters into forward exchange contracts in non-functional currencies and purchases and writes non-functional currency options in order to hedge the currency exposure on identifiable balance sheet items. In addition, the Company takes steps to reduce exposure by using "natural" hedging. The currency hedged items are usually denominated in NIS. The writing of options is part of a comprehensive currency hedging strategy. These transactions are for periods of less than one year. The counterparties to the derivatives is comprised of major banks and, in view of the current financial environment, the Company is monitoring the associated inherent credit risks. The above transactions do not qualify for hedge accounting.
	In December 2013, the Company entered into forward exchange contracts in respect of forecasted sales transactions at a notional amount of €11.2 million.
	Such transactions were entered into to reduce the exposure from sales denominated in euros. These transactions qualify for cash flow hedge accounting.
		b.	Interest rate swaps
	In February 2010, the Company entered into an interest rate swap agreement with a third party in respect to its $5.6 million principal amount long-term loan. The purpose of the transaction was to change the interest from floating rate to fixed rate. As a result of this agreement, the Company pays, starting March 2011 through February 2015, an effective interest rate of 8.37%, as compared to the original floating rate of one-month LIBOR plus 5.05%. At December 31, 2013, following the notification to the Bank regarding the early repayment of the long-term loan, see Note 7, this transaction no longer qualifies for hedge accounting.

RELATED_PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2013
RELATED PARTIES [Abstract]	'
RELATED PARTIES	'
	NOTE 15 - RELATED PARTIES:
		Year ended December 31
		2013		2012		2011
		U.S. dollars in thousands
	Directors' fees	$	143	$	21	$	6
	At December 31, 2013, there were 231,200 options outstanding with an average exercise price of $4.12 that were granted to members of the Board. At December 31, 2013, 195,160 out of these options were exercisable. As to restricted shares granted to the chairman and vice chairman of the Board of Directors, see Note 10d.

EARNINGS_LOSS_PER_SHARE

EARNINGS (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2013
EARNINGS (LOSS) PER SHARE [Abstract]	'
EARNINGS (LOSS) PER SHARE	'
	NOTE 16 - EARNINGS (LOSS) PER SHARE
	The following table sets forth the computation of basic and diluted earnings (loss) per share for the years indicated (in thousands, except per share amounts):
	Basic earnings (loss) per share:
		Year ended December 31
		2013			2012			2011
	Net income (loss)	$	11,395		$	4,782		$	(864	)
	Amount allocated to participating preferred shareholders		(6,439	)		(3,798	)
	Net income (loss) applicable to ordinary	$	4,956		$	984		$	(864	)
	shareholders - basic
	Weighted average ordinary shares outstanding		7,544,387			2,996,624			2,965,481
	Basic earnings (loss) per share	$	0.66		$	0.33		$	(0.29	)
	Diluted earnings (loss) per share:
	Net income (loss) applicable to ordinary	$	4,956		$	984		$	(864	)
	shareholders - diluted
	Weighted average number of shares used in the computation of basic earnings per share		7,544,387			2,996,624			2,965,481
	Add -
	additional shares from the assumed exercise of employee options and restricted shares		1,742,069			465,253
	vesting
	Weighted average number of shares used in the computation of diluted earnings (loss) per share		9,286,456			3,461,877			2,965,481
	Diluted earnings (loss) per share	$	0.53		$	0.28		$	(0.29	)
	For the year ended December 31, 2013, 13,600 options to employees, 52,020 restricted shares and all preferred shares (12,905,312) were excluded from the calculation of the diluted earnings per share for the year since their effect was anti-dilutive or certain performance conditions were not satisfied at the end of the year.
	For the year ended December 31, 2012, 1,100,580 options to employees and all warrants to preferred shareholders (211,548) and preferred shares (11,623,104) were excluded from the calculation of the diluted earnings per share for the year since their effect was anti-dilutive.
	For the year ended December 31, 2011, all outstanding options to employees (1,789,760), warrants to preferred shareholders (155,448) and preferred shares (11,342,468) were excluded from the calculation of the diluted loss per share for the year since their effect was anti-dilutive.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 17 - SUBSEQUENT EVENTS
	The Company evaluated subsequent events through February 13, 2014, the date on which the December 31, 2013 consolidated financial statements were issued.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policy)	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
General	'
		General
	Enzymotec Ltd. (the "Company" or "Enzymotec"), an Israeli company formed in 1998, which, together with its subsidiaries, develops, manufactures, markets and sells innovative bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies.
	The Company's sales are made to companies that market dietary supplements, to distributors related to those companies, to nutrition companies that provide balanced nutrition to babies and to pharmaceutical companies that market the products as treating diseases by providing the body with optimal amounts of substances which are natural to the body. In the VAYA Pharma segment, the majority of the products are sold directly to customers in the US through wholesalers. Outside the US, sales are made through leading pharmaceutical companies. As to sales by geographic locations and major customers, see Note 5.
	In June 2007, the Company entered into a joint collaboration agreement with a Swedish vegetable oil company (the "Partner") for the manufacture, marketing and sale of products to the infant food industry and established Advance Lipids AB, a Swedish company jointly owned by both parties in equal proportions ("Advanced Lipids") for this purpose.
Basis of presentation	'
	Basis of presentation
	On September 12, 2013, the Company effected a bonus share distribution under which: (i) 67 bonus shares were issued for each share outstanding prior to such distribution; and (ii) the conversion rate for each preferred share, option and warrant was adjusted to reflect such bonus share distribution. For accounting purposes, this transaction was recorded as a share split and accordingly (unless otherwise noted), all shares, options, warrants and earnings (losses) per share amounts have been adjusted retroactively for all years presented in these consolidated financial statements.
Use of estimates in preparation of financial statements	'
	Use of estimates in preparation of financial statements
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to contingencies.
Functional currency	'
	Functional currency
	The U.S. dollar ("dollar") is the currency of the primary economic environment in which the operations of the Company are conducted. The majority of the Company's sales are denominated in dollars; the majority of the Company's expenses are incurred in dollars; and the majority of the Company's financing has been provided in dollars.
	Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the consolidated statements of operations and comprehensive income (loss) (indicated below), the following exchange rates are used: (i) for transactions - exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are recorded in financial income (expenses), as appropriate.
	The functional currency of the Company's equity investee, Advanced Lipids, is the Swedish Krona, which is the currency of the primary economic environment in which the operations of Advanced Lipids are conducted. Currency translation adjustments are presented within other comprehensive income (loss).
Principles of consolidation	'
	Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been fully eliminated. Profits from intercompany sales have also been eliminated.
Investment in equity investee	'
	Investment in equity investee
	The Company's investment in Advanced Lipids, which is a less-than-majority-owned entity in which the Company exercises significant influence over operating and financial policies, is accounted for using the equity method of accounting. Under the equity method, original investments are recorded at cost and adjusted by the Company's share of undistributed profits or losses of such company. The Company's profits from Advanced Lipids have been reflected as "share in profits of equity investee" in the consolidated statements of operations and comprehensive income (loss).
Cash equivalents	'
	Cash equivalents
	The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that are not restricted as to withdrawal or use, to be cash equivalents.
Inventories	'
	Inventories
	Inventories include raw materials and finished products and are valued at the lower of cost or market. The cost of inventories is determined as follows:
	Raw materials and supplies - on the "first-in, first-out" basis;
	Products in process and finished products: the raw and packaging materials on the "first-in, first-out" basis; the capitalized production cost - mainly on an average basis over the production period.
Property, plant and equipment	'
	Property, plant and equipment
	These assets are stated at cost, net of accumulated depreciation and amortization. The assets are depreciated by the straight-line method on the basis of their estimated useful lives.
	Annual rates of depreciation are as follows:
			%
	Computers and software			33
	Buildings			2
	Vehicles			15
	Manufacturing equipment			7 - 10
	Laboratory equipment (mainly 15%)			7 - 20
	Furniture and office equipment			6 - 15
	Leasehold improvements are amortized by the straight-line method over the term of the lease, which is shorter than the estimated useful life of the improvements.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the assets is less than the carrying amount of such assets, an impairment loss would be
	recognized. The assets would be written down to their estimated fair values, calculated based on the present value of expected future cash flows (discounted cash flows), or some other fair value measure.
	As of December 31, 2013, 2012 and 2011, the Company did not recognize an impairment loss for its long-lived assets.
Revenue recognition	'
	Revenue recognition
	The Company recognizes revenue from sales of its products to customers, including distributors, when persuasive evidence of sales arrangement exists, delivery has occurred, the sales price is fixed or determinable and collectability is reasonably assured. See also Note 4 for timing of revenue recognition related to the Company's joint collaboration agreement. The Company provides a right of return to its U.S. distributors upon expiry of the medical food products sold in the Vaya Pharma segment. Accordingly, the Company records a reserve for estimated sales returns based on historical experience since the beginning of 2011, as well as specific factors, such as levels of inventory in the distribution channel, product dating and expiration. Returns to date have been inconsequential. Revenues from product sales are also recorded net of cash discounts and distribution fees, which can be reasonably estimated.
Research and development expenses	'
	Research and development expenses
	Research and development expenses are charged to income as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. The main components of the research and development expenses are salaries and related expenses, laboratory, clinical research and regulatory related expenses.
Contingencies	'
	Contingencies
	Certain conditions may exist as of the date of the financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. Management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	Management applies the guidance in Accounting Standards Codification ("ASC") 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material are disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantees are disclosed.
Income taxes	'
		Income taxes
	Deferred income taxes are determined by the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the tax rates expected to be in effect at the time when these differences reverse. Valuation allowances in respect of the deferred tax assets are provided when it is more likely than not that all or a portion of the deferred income tax assets will not be realized. See Note 12g for additional information regarding deferred taxes.
	The Company assesses its valuation allowance considering different indicators, including profitability of the different entities in the different tax jurisdictions, the ability to utilize the deferred tax assets in subsequent years, etc.
	Upon the distribution of dividends from the tax-exempt income of an "Approved Enterprise" or "Benefitted Enterprise" (see also Note 12 a (3)), the amount distributed is subject to tax at the rate that would have been applicable had the Company not been exempted from payment thereof. The Company intends to permanently reinvest the amounts of tax exempt income and it does not intend to distribute such dividends. Therefore, no deferred income taxes have been provided in respect of such tax-exempt income.
	The Company may incur an additional tax liability in the event of an inter-company dividend distribution from foreign subsidiaries; no additional deferred income taxes have been provided, since it is the Company's policy not to distribute dividends in the foreseeable future that may result in additional tax liability.
	Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been taken into account in computing deferred income taxes, as it is the Company's intent and ability to hold these investments.
	Tax benefits recognized in the consolidated financial statements are those that management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit management deems more likely than not to be sustained.
Share-based compensation	'
	Share-based compensation
	The Company accounts for employees and directors share-based compensation awards classified as equity awards using the grant-date fair value method. The fair value of share-based compensation transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. Performance-based awards are expensed over the requisite service period based on achievement of performance criteria.
	The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the straight-line method based on the multiple-option award approach.
	When options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
Shipping and handling costs	'
	Shipping and handling costs
	Shipping and handling costs on sales are classified as a component of cost of revenues.
Advertising	'
	Advertising
	Costs related to advertising and promotion of products, are charged to selling and marketing expense as incurred.
Earnings (loss) per share	'
	Earnings (loss) per share
	Basic earnings (loss) per share are computed by dividing net income or loss applicable to ordinary shareholders by the weighted average number of shares of the Company's ordinary shares outstanding for each period.
	Diluted earnings (loss) per share are calculated by dividing net income or loss applicable to ordinary shareholders by the fully-diluted weighted-average number of ordinary shares outstanding during each
	period. Potentially dilutive shares are comprised of: (i) incremental ordinary shares issuable upon the exercise of share options, restricted shares or warrants, using the treasury stock method; and (ii) shares issuable upon conversion of preferred shares using the "if-converted" method. Performance-vested share awards are included in the average diluted shares outstanding each period if the performance criteria have been met at the end of the respective periods.
	Basic and diluted earnings (loss) per share are presented in conformity with the two-class method for participating securities for the period prior to their conversion upon the Company's initial public offering in October 2013 when all preferred shares were converted into ordinary shares. Under this method the earnings per share for each class of shares (ordinary shares and preferred shares) are calculated assuming 100% of the Company's earnings are distributed as dividends to each class of shares based on their contractual rights. In addition, since preferred shareholders do not participate in losses, for the year ended December 31, 2011 preferred shares are not included in the computation of basic and diluted net loss per share.
Derivatives	'
	Derivatives
	The Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts, and written and purchased currency options). The transactions are designed to hedge the Company's currency exposure.
	Derivatives that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of "financial expenses - net" in the consolidated statements of operations and comprehensive income (loss).
	For derivatives that qualify for cash-flow hedges, the effective portion of these derivatives' fair value is initially reported as a component of other comprehensive income or loss.
	For derivatives that do not qualify for hedge accounting, the cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
	For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives are hedging.
Fair value measurement	'
	Fair value measurement
	The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
	The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of bank borrowing also approximates the carrying value since it bears interest at rates close to the prevailing market rates.
	The three levels of inputs that may be used to measure fair value are as follows:
	Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
	Level 3 - Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Concentration of credit risks, trade receivables and suppliers.	'
	Concentration of credit risks, trade receivables and suppliers.
	Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and trade receivables. The Company deposits cash and cash equivalents with highly rated financial institutions, mainly Israeli and U.S. banks. Deposits in U.S. banks are federally insured up to $250,000 per account. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.
	The Company performs ongoing credit evaluations to estimate the need for maintaining reserves for potential credit losses. An allowance for doubtful accounts is recognized on a specific basis with respect to those amounts that the Company has determined to be doubtful of collection. No allowance for doubtful accounts was recorded in the years ended December 31, 2013, 2012 and 2011.
	At December 31, 2013, two customers accounted for more than 10% of gross accounts receivable with balances of $4,172,000 and $3,688,000.
	At December 31, 2012, one customer accounted for more than 10% of gross accounts receivable with a balance of $2,440,000.
	The Company is dependent on third parties to supply krill meal, an essential raw material for the production of krill oil, which accounted for 53.8% and 49.8% of total net revenues in 2013 and 2012, respectively. The Company currently purchases krill meal pursuant to a memorandum of understanding with the owners of a vessel that harvests Antarctic krill. It also purchases krill meal from several other suppliers, subject to availability. There are a limited number of vessels capable of producing krill meal onboard. In 2013, a distribution company from which the Company previously purchased krill meal declared bankruptcy and, although no material disruption to the krill meal supply occurred and the Company was able to make alternative arrangements with the owner of the vessel, if the Company, for any reason, is no longer able to obtain the krill meal from a supplier on terms reasonable to it, or at all, this would have a material adverse effect on its results of operations and financial condition.
Recently issued accounting pronouncements	'
		Recently issued accounting pronouncements
	In February 2013, the FASB issued ASU 2013-04, which provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, except for obligations addressed within existing guidance under U.S. generally accepted accounting principles. The update is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2013, with early adoption permitted. The Company believes that the adoption of this standard will not have a material impact on its consolidated financial statements.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of Annual Rates of Depreciation	'
		%
	Computers and software		33
	Buildings		2
	Vehicles		15
	Manufacturing equipment		7 - 10
	Laboratory equipment (mainly 15%)		7 - 20
	Furniture and office equipment		6 - 15

INITIAL_PUBLIC_OFFERING_IPO_Ta

INITIAL PUBLIC OFFERING ("IPO") (Tables)	12 Months Ended
	Dec. 31, 2013
INITIAL PUBLIC OFFERING ("IPO")[Abstract]	'
Schedule of Number of Ordinary Shares Outstanding Following the IPO	'
		Number of shares
	Ordinary shares outstanding at September 30, 2013		3,167,304
	Ordinary shares issued following the conversion of the preferred shares		12,905,312
	outstanding
	Ordinary shares issued following the exercise of preferred share warrants and subsequent conversion		385,084
	Ordinary shares issued in the IPO (including the underwriters' option to purchase additional shares)		5,073,800
	Total ordinary shares outstanding at October 2, 2013		21,531,500

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
PROPERTY, PLANT AND EQUIPMENT [Abstract]	'
Schedule of Property and Equipment	'
		31-Dec
		2013		2012
		U.S. dollars in thousands
	Manufacturing equipment	$	17,993	$	14,365
	Buildings		10,269		8,985
	Laboratory equipment		2,792		2,442
	Land*		951		951
	Furniture, office equipment and computers		1,082		886
	Leasehold improvements		161		161
	Vehicles		18		42
	Advances on account of acquisition of machinery and equipment		119		636
			33,385		28,468
	Less: accumulated depreciation and amortization		7,021		5,504
		$	26,364	$	22,964

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2013
SEGMENT INFORMATION [Abstract]	'
Schedule of Operating Segments	'
	Segment data for the year ended December 31, 2013 is as follows:
			Nutrition		Vaya			Total		Elimination**			Consolidated
					Pharma
			U.S. dollars in thousands
	Net revenues from external customers		$	76,167	$	4,444		$	80,611	$	(15,636	)	$	64,975
	Cost of revenues*			45,804		1,255			47,059		(14,981	)		32,078
	Gross profit*			30,363		3,189			33,552		(655	)		32,897
	Operating expenses*			13,009		6,020			19,029					19,029
	Depreciation and amortization			1,415		136
	Adjusted EBITDA		$	18,769	$	(2,695	)
	IPO related bonus													1,000
	Share-based compensation expense													1,109
	Operating Income												$	11,759
	Financial expenses - net													531
	Income before taxes on income												$	11,228
		*	Including depreciation and amortization but excluding share-based compensation expense and IPO-related bonus.
		**	Representing the change from proportionate consolidation to the equity method of accounting.
	Segment data for the year ended December 31, 2012 is as follows:
			Nutrition		Vaya Pharma			Total		Elimination**			Consolidated
			U.S. dollars in thousands
	Net revenues from external customers		$	44,380	$	1,832		$	46,212	$	(8,345	)	$	37,867
	Cost of revenues*			27,297		588			27,885		(8,087	)		19,798
	Gross profit*			17,083		1,244			18,327		(258	)		18,069
	Operating expenses*			7,850		4,637			12,487					12,487
	Depreciation and amortization			1,304		118
	Adjusted EBITDA		$	10,537	$	(3,275	)
	Share-based compensation expense													267
	Operating Income													5,315
	Financial expenses - net													539
	Income before taxes on income												$	4,776
		*	Including depreciation and amortization but excluding share-based compensation expense.
		**	Representing the change from proportionate consolidation to the equity method of accounting.
	Segment data for the year ended December 31, 2011 is as follows:
			Nutrition		Vaya Pharma			Total		Elimination**			Consolidated
			U.S. dollars in thousands
	Net revenues from external customers		$	27,266	$	739		$	28,005	$	(4,986	)	$	23,019
	Cost of revenues*			17,955		447			18,402		(4,942	)		13,460
	Gross profit*			9,311		292			9,603		(44	)		9,559
	Operating expenses*			7,735		1,828			9,563					9,563
	Depreciation and amortization			1,168		65
	Adjusted EBITDA		$	2,744	$	(1,471	)
	Share-based compensation expense													343
	Operating loss													(347	)
	Financial expenses- net													416
	Loss before taxes on income												$	(763	)
		*	Including depreciation and amortization but excluding share-based compensation expense.
		**	Representing the change from proportionate consolidation to the equity method of accounting.
Schedule of Revenues by Geographic Area	'
			Year ended December 31
			2013		2012			2011
			U.S. dollars in thousands
	North America		$	35,458	$	17,487		$	14,394
	Europe			10,382		6,828			3,557
	Australia			10,811		11,763			1,474
	Asia			7,735		1,497			3,094
	Israel			589		292			500
	Total revenue		$	64,975	$	37,867		$	23,019
Schedule of Revenue from Sales by Major Products	'
			Year ended December 31
			2013		2012			2011
			U.S. dollars in thousands
	Krill oil		$	34,926	$	18,841		$	9,701
	InFat		$	16,666	$	8,183		$	3,533
	Sharp PS		$	5,248	$	4,978		$	3,589
Schedule of Revenues of Principal Customers	'
			Year ended December 31
			2013		2012			2011
	U.S. dollars in thousands
	Customer A		$	7,692	$	9,426		$	1,179
	Customer B		$	1,301	$	2,130		$	2,801
	Customer C		$	2,329	$	2,586		$	2,626
	Customer D		$	9,833	$	595		$	-

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
INVENTORIES [Abstract]	'
Schedule of Inventories	'
		31-Dec
		2013		2012
		U.S. dollars in thousands
	Raw materials and supplies	$	6,550	$	4,663
	In-process inventories	$	3,790		2,360
	Finished goods	$	1,603		2,336
		$	11,943	$	9,359

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
SHAREHOLDERS' EQUITY [Abstract]	'
Schedule of Assumptions Used to Value Options Granted	'
			2013			2012			2011
	Dividend yield			0	%		0	%		0	%
	Expected volatility			67	%		60	%		77	%
	Risk-free interest rate			1.8	%		2.2	%		1.8	%
	Contractual term			10 years			10 years			10 years
	Early exercise multiple			215% - 246	%		218% -  229	%		218% - 229	%
Schedule of Share Option Activity	'
			Year ended December 31
			2013						2012					2011
			Number of shares upon exercise			Weighted average exercise price*			Number of shares upon exercise			Weighted average exercise price*		Number of shares upon exercise			Weighted average
																	exercise price*
	Outstanding at the beginning of the year			1,866,940			2.13			1,789,760			2.08		1,576,648			1.92
	Granted			174,420			6.02			168,980			3.12		282,200			2.88
	Exercised			(47,940	)		0.15								(51,272	)		0.94
	Forfeited			(25,636	)		3.12			(91,800	)		3.12		(17,816	)		3.04
	Outstanding at the end of the year			1,967,784			2.51			1,866,940			2.13		1,789,760			2.08
	Exercisable at the end of the year			1,747,532			2.29			1,335,112			1.74		1,067,668			1.45
		*	In dollars per share.
Schedule of Stock Options Outstanding by Exercise Price Range	'
	Options outstanding											Options exercisable
	Exercise prices*		Shares upon exercise of options outstanding at end of year			Weighted average remaining contractual life			Aggregate intrinsic value			Shares upon exercise of options outstanding at end of year		Weighted average remaining contractual life			Aggregate intrinsic value (U.S. dollars in thousands)
									(U.S. dollars in thousands)
	0.0001			285,600			1.78			7,714			285,600		1.78			7,714
	0.001			27,200			0.96			735			27,200		0.96			735
	1.47			408,000			4.93			10,420			408,000		4.93			10420
	1.62			40,800			4.62			1,036			40,800		4.62			1,036
	3.12			1,031,764			6.98			24,649			870,536		6.97			20,797
	5.34			160,820			9.27			3,485			115,396		9.27			2,501
	14			13,600			9.76			177
				1,967,784			5.87			48,216			1,747,532		5.65			43,203
		*	In dollars per share
Schedule of Stock-Based Compensation Expense	'
			Year ended December 31
			2013			2012			2011
			U.S. dollars in thousands
	Cost of revenues		$	32		$	17		$	8
	Research and development expenses - net			56			60			72
	Selling and marketing expenses			77			40			84
	General and administrative expenses			944			150			179
			$	1,109		$	267		$	343
Schedule of Accumulated Other Comprehensive Income	'
			31-Dec
			2013			2012
			U.S. dollars in thousands
	Currency translation adjustment		$	25		$	14
	Unrealized loss from cash flow hedge*			(90	)		(261	)
			$	(65	)	$	(247	)
		*	During 2013, an amount of $261,000 in respect of unrealized loss from cash flow hedge was reclassified from accumulated other comprehensive loss into financial expenses.

TAXES_ON_INCOME_Tables

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2013
TAXES ON INCOME [Abstract]	'
Schedule of Income (Loss) before Taxes on Income	'
		Year ended December 31
		2013			2012			2011
		U.S. dollars In thousands
	Israel	$	10,414		$	4,360		$	(1,036	)
	Non-Israeli Subsidiaries		814			416			273
		$	11,228		$	4,776		$	(763	)
Schedule of Taxes on Income - Current	'
	non-Israeli Subsidiaries	$	324		$	180		$	137
Reconciliation of Theoretical Tax Expense to Actual Tax Expense	'
		Year ended December 31
		2013			2012			2011
		U.S. dollars in thousands
	Income (loss) before taxes on income	$	11,228		$	4,776		$	(763	)
	Theoretical tax expenses (benefit) at the statutory rate (2013 and 2012 - 25%; 2011 - 24%)		2,807			1,194			(183	)
	Increase (decrease) in taxes on income due to:
	Computation of deferred taxes at a rate, which is different than statutory rate		(2,033	)		(1,157	)		166
	Difference between income reported for tax purposes and income for financial reporting		(754	)
	purposes - mainly dollar - NIS differences
	Non-deductible expenses - mainly share-based compensation expense		183			74			89
	Different effective tax rates applicable to the subsidiaries		121			69			65
		$	324		$	180		$	137

SUPPLEMENTARY_FINANCIAL_STATEM1

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2013
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]	'
Schedule of Accounts Receivable	'
		31-Dec
		2013			2012
		U.S. dollars in thousands
	Advance to supplier	$	1,153		$	1,695
	Institutions		1,065			1,024
	Chief Scientist		77			153
	Fair value of derivatives		1			251
	Prepaid expenses and sundry		442			234
		$	2,738		$	3,357
Schedule of Accounts Payable and Accruals	'
	Employees and payroll related institutions	$	2,470		$	1,515
	Provision for vacation and recreation pay		426			373
	Royalties payable		57			23
	Fair value of derivatives		222			261
	Accrued expenses and sundry		3,203			910
		$	6,378		$	3,082
Schedule of Research and Development Expenses	'
		Year ended December 31
		2013			2012			2011
		U.S. dollars in thousands
	Total expenses	$	6,144		$	4,876		$	4,426
	Less - participation and grants		197			265			566
		$	5,947		$	4,611		$	3,860
Schedule of Financial Expenses, Net	'
	Interest expenses and other bank charges	$	(595	)	$	(657	)	$	(590	)
	Interest income		50
	Foreign exchange gain (losses) - net		(82	)		(102	)		22
	Gain (losses) in respect of derivatives - net		96			220			152
		$	(531	)	$	(539	)	$	(416	)

FAIR_VALUE_MEASUREMENT_Tables

FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'
Schedule of Financial Assets and Liabilities Measured at Fair Value	'
		31-Dec-13
		U.S. dollars in thousands
		Level 1		Level 2
	Cash and cash equivalents - cash deposits and other	$	74,430
	Derivatives:
	Interest rate swap (liabilities)				($132	)
	Forward contracts (liabilities)				(90	)
	Forward contracts and currency options (assets)				1
		$	74,430	$	(221	)
		31-Dec-12
		U.S. dollars in thousands
		Level 1		Level 2
	Cash and cash equivalents - cash deposits and other	$	2,729
	Derivatives:
	Interest rate swap (liabilities)			$	(261	)
	Forward contracts and currency options (assets)				251
		$	2,729	$	(10	)

RELATED_PARTIES_Tables

RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2013
RELATED PARTIES [Abstract]	'
Schedule of Related Party Balances and Transactions	'
		Year ended December 31
		2013		2012		2011
		U.S. dollars in thousands
	Directors' fees	$	143	$	21	$	6

EARNINGS_LOSS_PER_SHARE_Tables

EARNINGS (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
EARNINGS (LOSS) PER SHARE [Abstract]	'
Schedule of Basic and Diluted Earnings (Loss) Per Share	'
		Year ended December 31
		2013			2012			2011
	Net income (loss)	$	11,395		$	4,782		$	(864	)
	Amount allocated to participating preferred shareholders		(6,439	)		(3,798	)
	Net income (loss) applicable to ordinary	$	4,956		$	984		$	(864	)
	shareholders - basic
	Weighted average ordinary shares outstanding		7,544,387			2,996,624			2,965,481
	Basic earnings (loss) per share	$	0.66		$	0.33		$	(0.29	)
	Diluted earnings (loss) per share:
	Net income (loss) applicable to ordinary	$	4,956		$	984		$	(864	)
	shareholders - diluted
	Weighted average number of shares used in the computation of basic earnings per share		7,544,387			2,996,624			2,965,481
	Add -
	additional shares from the assumed exercise of employee options and restricted shares		1,742,069			465,253
	vesting
	Weighted average number of shares used in the computation of diluted earnings (loss) per share		9,286,456			3,461,877			2,965,481
	Diluted earnings (loss) per share	$	0.53		$	0.28		$	(0.29	)

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	0 Months Ended		12 Months Ended				12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 12, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
			Accounts Receivable [Member]	Accounts Receivable [Member]	Accounts Receivable [Member]	Accounts Receivable [Member]	Sales Revenue [Member]	Sales Revenue [Member]
					Major Customer One [Member]	Major Customer Two [Member]	Krill Oil [Member]	Krill Oil [Member]
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'	'	'	'	'
Shares issued in bonus share distribution	67	'	'	'	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'
Concentration risk percentage	'	'	10.00%	10.00%	'	'	53.80%	49.80%
Number of major customers	'	'	2	1	'	'	'	'
Gross accounts receivable	'	'	'	$2,440	$4,172	$3,688	'	'
FDIC insured limit	'	$250	'	'	'	'	'	'

SIGNIFICANT_ACCOUNTING_POLICIE4

SIGNIFICANT ACCOUNTING POLICIES (Depreciation Rates for Property, Plant and Equipment) (Details)	12 Months Ended
	Dec. 31, 2013
Computers and software [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	33.00%
Buildings [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	2.00%
Vehicles [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	15.00%
Manufacturing equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	7.00%
Manufacturing equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	10.00%
Laboratory equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	7.00%
Laboratory equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	20.00%
Furniture and office equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	6.00%
Furniture and office equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Depreciation rate	15.00%

INITIAL_PUBLIC_OFFERING_IPO_De

INITIAL PUBLIC OFFERING ("IPO") (Details) (USD $)	12 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 02, 2013	Oct. 02, 2013
				IPO [Member]	IPO [Member]
					Ordinary shares [Member]
Initial Public Offering [Line Items]	'	'	'	'	'
Balance, shares	2,996,624	'	'	'	3,167,304
Ordinary shares issued following the conversion of the preferred shares outstanding	'	'	'	'	12,905,312
Issuance of ordinary shares in an initial public offering, net of issuance costs, shares	'	'	'	5,073,800	5,073,800
Ordinary shares issued following the exercise of preferred share warrants and subsequent conversion	'	'	'	'	385,084
Balance, shares	21,564,820	2,996,624	'	'	21,531,500
Vested	'	'	'	'	262,888
Options expected to vest	'	'	'	'	224,740
Restricted shares, granted	'	'	'	'	9,520
Share-based compensation expense	$1,109	$267	$343	'	$900
IPO-related employee bonus expense	1,000	'	'	'	1,000
IPO- related employee bonus conditions	'	'	'	'	'Such bonuses were partly subject to the closing of the IPO ($0.5 million) and partly subject to the Company's market capitalization exceeding an agreed upon level for at least 30 trading days within 24 months following its IPO ($0.5 million).
Proceeds from initial public offering, net of issuance costs of $8.2 million	$62,838	'	'	$62,838	'
IPO price per share	'	'	'	$14	'
IPO option to purchase an additional shares, number of shares	'	'	'	661,800	'

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'		'		'
Cost	$33,385		$28,468		'
Less: accumulated depreciation and amortization	7,021		5,504		'
Net	26,364		22,964		'
Depreciation and amortization	1,551		1,422		1,233
Useful life of long-term leasehold rights	'98 years		'		'
Manufacturing equipment [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	17,993		14,365		'
Buildings [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	10,269		8,985		'
Laboratory equipment [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	2,792		2,442		'
Land [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	951	[1]	951	[1]	'
Furniture, office equipment and computers [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	1,082		886		'
Leasehold improvements [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	161		161		'
Vehicles [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	18		42		'
Advances on account of acquisition of machinery and equipment [Member]	'		'		'
Property, Plant and Equipment [Line Items]	'		'		'
Cost	$119		$636		'
[1]	*Land includes long-term leasehold rights in Israel, with useful lives of 98 years.

JOINT_COLLABORATION_AGREEMENT_

JOINT COLLABORATION AGREEMENT (Details) (Equity Method Investee Advanced Lipids [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity Method Investee Advanced Lipids [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Ownership percentage of joint collaboration	50.00%	'	'
Sales through joint collaboration	$16,666	$8,183	$3,533
Receivable balance through joint collaboration	$5,370	$3,411	'
Agreement terms	'The joint collaboration agreement's initial term ends on December 31, 2016. Thereafter the agreement will be automatically extended for consecutive periods of three years, unless terminated by a notice of either party at least 12 months prior to its expiration.	'	'

SEGMENT_INFORMATION_Narrative_

SEGMENT INFORMATION (Narrative) (Details) (Equity Method Investee Advanced Lipids [Member])	Dec. 31, 2013
Equity Method Investee Advanced Lipids [Member]	'
Segment Reporting Information [Line Items]	'
Ownership percentage of joint collaboration	50.00%

SEGMENT_INFORMATION_Schedule_o

SEGMENT INFORMATION (Schedule of Reportable Operating Segments) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'		'		'
Net revenues	$64,975		$37,867		$23,019
Cost of revenue	32,078	[1]	19,798	[1]	13,460	[1]
Gross profit	32,897	[1]	18,069	[1]	9,559	[1]
Operating expenses	19,029	[1]	12,487	[1]	9,563	[1]
Depreciation and amortization	1,551		1,422		1,233
Adjusted EBITDA	'		'		'
IPO related bonus	1,000		'		'
Share-based compensation expense	1,109		267		343
Operating Income	11,759		5,315		-347
FINANCIAL EXPENSES - net	531		539		416
INCOME (LOSS) BEFORE TAXES ON INCOME	11,228		4,776		-763
Operating Segments [Member]	'		'		'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'		'		'
Net revenues	80,611		46,212		28,005
Cost of revenue	47,059	[1]	27,885	[1]	18,402	[1]
Gross profit	33,552	[1]	18,327	[1]	9,603	[1]
Operating expenses	19,029	[1]	12,487	[1]	9,563	[1]
Adjusted EBITDA	'		'		'
Intersegment Eliminations [Member]	'		'		'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'		'		'
Net revenues	-15,636	[2]	-8,345	[2]	-4,986	[2]
Cost of revenue	-14,981	[1]	-8,087	[1]	-4,942	[1]
Gross profit	-655	[1]	-258	[1]	-44	[1]
Adjusted EBITDA	'		'		'
Nutrition [Member] | Operating Segments [Member]	'		'		'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'		'		'
Net revenues	76,167		44,380		27,266
Cost of revenue	45,804	[1]	27,297	[1]	17,955	[1]
Gross profit	30,363	[1]	17,083	[1]	9,311	[1]
Operating expenses	13,009	[1]	7,850	[1]	7,735	[1]
Depreciation and amortization	1,415		1,304		1,168
Adjusted EBITDA	18,769		10,537		2,744
VAYA Pharma [Member] | Operating Segments [Member]	'		'		'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'		'		'
Net revenues	4,444		1,832		739
Cost of revenue	1,255	[1]	588	[1]	447	[1]
Gross profit	3,189	[1]	1,244	[1]	292	[1]
Operating expenses	6,020	[1]	4,637	[1]	1,828	[1]
Depreciation and amortization	136		118		65
Adjusted EBITDA	($2,695)		($3,275)		($1,471)
[1]	Including depreciation and amortization but excluding share-based compensation expense.
[2]	Representing the change from proportionate consolidation to the equity method of accounting.

SEGMENT_INFORMATION_Schedule_o1

SEGMENT INFORMATION (Schedule of Geographic Information) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Net revenues	$64,975	$37,867	$23,019
North America [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Net revenues	35,458	17,487	14,394
Europe [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Net revenues	10,382	6,828	3,557
Australia [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Net revenues	10,811	11,763	1,474
Asia [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Net revenues	7,735	1,497	3,094
Israel [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Net revenues	$589	$292	$500

SEGMENT_INFORMATION_Schedule_o2

SEGMENT INFORMATION (Schedule of Sale by Customer) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue, Major Customer [Line Items]	'	'	'
Net revenues	$64,975	$37,867	$23,019
Customer A [Member] | Nutrition [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Net revenues	7,692	9,426	1,179
Customer B [Member] | Nutrition [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Net revenues	1,301	2,130	2,801
Customer C [Member] | Nutrition [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Net revenues	2,329	2,586	2,626
Customer D [Member] | Nutrition [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Net revenues	$9,833	$595	'

SEGMENT_INFORMATION_Schedule_o3

SEGMENT INFORMATION (Schedule of Sales by Product) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue from External Customer [Line Items]	'	'	'
Net revenues	$64,975	$37,867	$23,019
Krill Oil [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Net revenues	34,926	18,841	9,701
InFat [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Net revenues	16,666	8,183	3,533
Sharp PS [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Net revenues	$5,248	$4,978	$3,589

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
INVENTORIES [Abstract]	'	'
Raw materials and supplies	$6,550	$4,663
In-process inventories	3,790	2,360
Finished goods	1,603	2,336
Total	$11,943	$9,359

BORROWINGS_Details

BORROWINGS (Details) (USD $)	Sep. 30, 2009	Dec. 31, 2013	Dec. 31, 2011	Sep. 30, 2009	31-May-12	Sep. 30, 2009	Sep. 30, 2009	Dec. 31, 2013	Feb. 28, 2010
		Short-term Line of Credit [Member]	Short-term Line of Credit [Member]	Short-term Line of Credit [Member]	Short-term Line of Credit [Member]	Long-term Loan One [Member]	Long-term Loan Two [Member]	Long-term Loan Two [Member]	Interest Rate Swap [Member]
					Maximum [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Debt, face amount	'	'	'	'	'	$1,400,000	$5,600,000	'	$5,600,000
Debt instrument, variable interest reference rate	'	'	'	'	'	'Annual LIBOR	'One month LIBOR	'	'
Interest spread on variable rate	'	'	'	'	'	3.60%	5.05%	'	'
Repayment terms	'	'	'	'	'	'24 Monthly Installments	'96 Monthly Installments	'	'
Date of first required payment	'	'	'	'	'	31-Jan-10	31-Jan-12	'	1-Mar-11
Debt instrument, maturity date	'	'	'	'	'	'	'	'	28-Feb-15
Period loan was extended	'	'	'	'	'	'	'8 years	'	'
Annual payment amount	'	'	'	'	'	'	700,000	'	'
Frequency of payment	'	'	'	'	'	'	'Monthly	'	'
Effective interest rate	'	'	'	'	'	'	'	'	8.37%
Financial expenses	'	'	'	'	'	'	'	282,000	'
Revolving credit facility, maximum borrowing amount	'	'	'	3,600,000	7,600,000	'	'	'	'
Increase (decrease) in line of credit	'	'	5,600,000	'	'	'	'	'	'
Percentage of consolidated net revenues	'	'	'	'	20.00%	'	'	'	'
Outstanding borrowings	$10,600,000	'	'	'	'	'	'	'	'
Credit facility expiration date	'	31-Dec-13	'	'	'	'	'	'	'

EMPLOYEE_RIGHTS_UPON_RETIREMEN1

EMPLOYEE RIGHTS UPON RETIREMENT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]	'	'	'
Contributions made to pension plan and other post retirement obligations	$156	$139	$158
Pension and other post retirement benefit plans expenses	506	284	317
Contribution plan funding	230	145	120
Gain (loss) on pension and other post retirement benefit plans	154	74	-58
Expected insurance contribution, year ending December 31, 2014	530	'	'
Expected insurance contribution attributable to contribution plan	$365	'	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2000

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Royalties [Member]

Royalties [Member]

Royalties [Member]

Royalties [Member]

Operating Lease [Member]

Operating Lease [Member]

Operating Lease [Member]

Litigation [Member]

Litigation [Member]

Litigation [Member]

Financial And Other Covenants [Member]

Chief Scientist [Member]

Chief Scientist [Member]

Chief Scientist [Member]

The U.S. Partner [Member]

USD ($)

USD ($)

USD ($)

Plaintiff Seeking Finders Fee [Member]

Plaintiff Seeking Finders Fee [Member]

Plaintiff Seeking Finders Fee [Member]

USD ($)

USD ($)

Minimum [Member]

Maximum [Member]

USD ($)

USD ($)

ILS

USD ($)

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

'

'

'

'

'

'

'

$419,000

'

'

'

'

'

'

2015

'

'

'

'

'

'

'

277,000

'

'

'

'

'

'

2016

'

'

'

'

'

'

'

192,000

'

'

'

'

'

'

2017

'

'

'

'

'

'

'

9,000

'

'

'

'

'

'

Total operating lease expense

'

'

'

'

'

'

'

897,000

'

'

'

'

'

'

Lease expense

'

'

'

'

'

'

'

452,000

355,000

276,000

'

'

'

'

Percentage rate of royalty owed

'

'

'

'

3.00%

5.00%

'

'

'

'

'

'

'

'

Accrued royalties

'

'

'

3,000,000

'

'

370,000

'

'

'

'

'

'

'

Royalty expenses

101,000

40,000

416,000

'

'

'

'

'

'

'

'

'

'

'

Royalty terms

'

'

'

'Under the terms of the Company's funding from the Chief Scientist, royalties of 3% - 5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked with the addition of annual interest at LIBOR rate).

'

'

'

'

'

'

'

'

'

'

Damages paid to plaintiff in lawsuit

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

Damages being sought

'

'

'

'

'

'

'

'

'

'

1,800,000

6,200,000

'

'

Investor's investment must exceed, amount

'

'

'

'

'

'

'

'

'

'

'

'

500,000

20,000,000

Percentage rate of shareholders' equity that must exceed total assets

'

'

'

'

'

'

'

'

'

'

'

'

'

45.00%

Adjusted EBITDA must exceed, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,500,000

Additional terms of financial covenant

'

'

'

'

'

'

'

'

'

'

'

'

'

'The ratio between Net Debt (defined as all liabilities to banks and financial institutions minus the company's cash and cash equivalents) and Adjusted EBITDA (as defined in the Financing Agreement) must be below 5 in 2012 and below 4 in 2013 and thereafter.

SHAREHOLDERS_EQUITY_Narrative_

SHAREHOLDERS' EQUITY (Narrative) (Details)

0 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Sep. 12, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Nov. 30, 2013

Aug. 31, 2013

Mar. 31, 2012

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2011

Sep. 02, 2013

USD ($)

USD ($)

USD ($)

ILS

ILS

USD ($)

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Service Providers [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Share Purchase Agreement [Member]

Series B2 Preferred Stock [Member]

Series B2 Preferred Stock [Member]

Series B2 Preferred Stock [Member]

Series B2 Preferred Stock [Member]

Ordinary shares [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

ILS

ILS

ILS

ILS

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of ordinary shares in an initial public offering, net of issuance costs

'

$62,838,000

'

'

'

'

'

'

'

'

'

'

'

'

$11,300,000

'

'

'

'

Preferred stock, par value per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.01

0.01

0.01

'

Proceeds received for issuance of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

5,650,000

'

'

'

'

'

Additional amount invested

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

Purchase price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.34

'

'

'

'

Total amount invested

'

'

'

'

'

'

'

'

'

'

'

'

'

12,500,000

'

'

'

'

'

Percentage of Series B2 Preferred shares purchased by investors

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

Shares issued in bonus share distribution

67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ordinary shares, shares authorized

'

100,000,000

3,399,618

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

Increase in authorized share capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

Ordinary shares, par value per share

'

'

'

'

0.01

0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

1,340,000

'

'

'

'

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total options granted

'

174,420

168,980

282,200

'

'

'

4,092,988

'

'

'

'

'

'

'

'

'

'

'

Ordinary shares, par value per share

'

'

'

'

0.01

0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

Options remained available

'

'

'

'

'

'

'

466,684

'

'

'

'

'

'

'

'

'

'

'

Outstanding options

'

1,967,784

1,866,940

1,789,760

'

'

1,576,648

'

'

'

56,100

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

Vesting percentage

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

Options, contractual term

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of options granted

'

'

'

'

'

'

'

$2.02

$0.23

$0.33

'

'

'

'

'

'

'

'

'

Period over which compensation expense will be recognized

'

'

'

'

'

'

'

'1 year 4 months 17 days

'

'

'

'

'3 years 3 months

'

'

'

'

'

'

Unrecognized compensation cost related to stock options

'

'

'

'

'

'

'

180,000

'

'

'

'

1,338,000

'

'

'

'

'

'

Exercise price

'

$2.51

[1]

$2.13

[1]

$2.08

[1]

'

'

$1.92

[1]

'

'

'

$1.73

'

'

'

'

'

'

'

'

Average remaining contractual life

'

'

'

'

'

'

'

'

'

'

'3 years 9 months 18 days

'

'

'

'

'

'

'

'

Restricted shares, granted

'

'

'

'

'

'

'

'

'

'

'

9,520

156,060

'

'

'

'

'

'

Vesting milestones

'

'

'

'

'

'

'

'

'

'

'

'

'(i) the vesting of 104,040 restricted shares is subject to the occurrence of a change of control event, as defined; and (ii) the vesting of 52,020 restricted shares is subject to: (a) the occurrence of a change of control event, as defined and (b) the achievement of a market cap milestone, as defined.

'

'

'

'

'

'

Restricted shares that will vest

'

'

'

'

'

'

'

'

'

'

'

'

104,040

'

'

'

'

'

'

Restricted shares that will vest after meeting market cap milestone

'

'

'

'

'

'

'

'

'

'

'

'

52,020

'

'

'

'

'

'

Share-based compensation expense

'

$1,109,000

$267,000

$343,000

'

'

'

'

'

'

'

$294,000

$377,000

'

'

'

'

'

'

[1]

In dollars per share.

SHAREHOLDERS_EQUITY_Schedule_o

SHAREHOLDERS' EQUITY (Schedule of Assumptions used in Fair Value of Option Granted) (Details) (Employee Stock Option [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	67.00%	60.00%	77.00%
Risk-free interest rate	1.80%	2.20%	1.80%
Contractual term	'10 years	'10 years	'10 years
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Early exercise multiple	215.00%	218.00%	218.00%
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Early exercise multiple	246.00%	229.00%	229.00%

SHAREHOLDERS_EQUITY_Schedule_o1

SHAREHOLDERS' EQUITY (Schedule of Stock Options Outstanding) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Number of shares issuable upon exercise	'		'		'
Outstanding at beginning of year	1,866,940		1,789,760		1,576,648
Granted	174,420		168,980		282,200
Exercised	-47,940		'		-51,272
Forfeited	-25,636		-91,800		-17,816
Outstanding at end of year	1,967,784		1,866,940		1,789,760
Exercisable at end of year	1,747,532		1,335,112		1,067,668
Weighted average exercise price	'		'		'
Outstanding at beginning of year	$2.13	[1]	$2.08	[1]	$1.92	[1]
Granted	$6.02	[1]	$3.12	[1]	$2.88	[1]
Exercised	$0.15	[1]	'	[1]	$0.94	[1]
Forfeited	$3.12	[1]	$3.12	[1]	$3.04	[1]
Outstanding at end of year	$2.51	[1]	$2.13	[1]	$2.08	[1]
Exercisable at end of year	$2.29	[1]	$1.74	[1]	$1.45	[1]
[1]	In dollars per share.

SHAREHOLDERS_EQUITY_Schedule_o2

SHAREHOLDERS' EQUITY (Schedule of Stock Options Outstanding by Exercise Price Range) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2010
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	1,967,784		'		'		'
Weighted average remaining contractual life	'5 years 10 months 13 days		'		'		'
Aggregate intrinsic Value	$48,216		'		'		'
Exercise price	$2.51	[1]	$2.13	[1]	$2.08	[1]	$1.92	[1]
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	1,747,532		'		'		'
Weighted average remaining contractual life	'5 years 7 months 24 days		'		'		'
Aggregate intrinsic value	43,203		'		'		'
Exercise price	$2.29	[1]	$1.74	[1]	$1.45	[1]	'
Closing share price	$27.01		'		'		'
.0001 [Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	285,600		'		'		'
Weighted average remaining contractual life	'1 year 9 months 11 days		'		'		'
Aggregate intrinsic Value	7,714		'		'		'
Exercise price	$0.00		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	285,600		'		'		'
Weighted average remaining contractual life	'1 year 9 months 11 days		'		'		'
Aggregate intrinsic value	7,714		'		'		'
Exercise price	$0.00		'		'		'
.001 [Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	27,200		'		'		'
Weighted average remaining contractual life	'11 months 16 days		'		'		'
Aggregate intrinsic Value	735		'		'		'
Exercise price	$0.00		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	27,200		'		'		'
Weighted average remaining contractual life	'11 months 16 days		'		'		'
Aggregate intrinsic value	735		'		'		'
Exercise price	$0.00		'		'		'
1.47 [Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	408,000		'		'		'
Weighted average remaining contractual life	'4 years 11 months 5 days		'		'		'
Aggregate intrinsic Value	10,420		'		'		'
Exercise price	$1.47		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	408,000		'		'		'
Weighted average remaining contractual life	'4 years 11 months 5 days		'		'		'
Aggregate intrinsic value	10,420		'		'		'
Exercise price	$1.47		'		'		'
1.62[Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	40,800		'		'		'
Weighted average remaining contractual life	'4 years 7 months 13 days		'		'		'
Aggregate intrinsic Value	1,036		'		'		'
Exercise price	$1.62		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	40,800		'		'		'
Weighted average remaining contractual life	'4 years 7 months 13 days		'		'		'
Aggregate intrinsic value	1,036		'		'		'
Exercise price	$1.62		'		'		'
3.12[Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	1,031,764		'		'		'
Weighted average remaining contractual life	'6 years 11 months 23 days		'		'		'
Aggregate intrinsic Value	24,649		'		'		'
Exercise price	$3.12		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	870,536		'		'		'
Weighted average remaining contractual life	'6 years 11 months 19 days		'		'		'
Aggregate intrinsic value	20,797		'		'		'
Exercise price	$3.12		'		'		'
5.34 [Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	160,820		'		'		'
Weighted average remaining contractual life	'9 years 3 months 7 days		'		'		'
Aggregate intrinsic Value	3,485		'		'		'
Exercise price	$5.34		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	115,396		'		'		'
Weighted average remaining contractual life	'9 years 3 months 7 days		'		'		'
Aggregate intrinsic value	2,501		'		'		'
Exercise price	$5.34		'		'		'
14 [Member]	'		'		'		'
Options outstanding	'		'		'		'
Shares upon exercise of options outstanding at end of year	13,600		'		'		'
Weighted average remaining contractual life	'9 years 9 months 4 days		'		'		'
Aggregate intrinsic Value	177		'		'		'
Exercise price	$14		'		'		'
Options exercisable	'		'		'		'
Shares upon exercise of options outstanding at end of year	'		'		'		'
Weighted average remaining contractual life	'		'		'		'
Aggregate intrinsic value	'		'		'		'
Exercise price	$14		'		'		'
[1]	In dollars per share.

SHAREHOLDERS_EQUITY_Allocation

SHAREHOLDERS' EQUITY (Allocation of Share-Based Compensation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	$1,109	$267	$343
Cost of revenues [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	32	17	8
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	56	60	72
Selling and Marketing Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	77	40	84
General and Administrative Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	$944	$150	$179

SHAREHOLDERS_EQUITY_Schedule_o3

SHAREHOLDERS' EQUITY (Schedule of Accumulated Other Comprehensive Loss) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
				Reclassification out of Accumulated Other Comprehensive Income [Member]
SHAREHOLDERS' EQUITY [Abstract]	'		'	'
Currency translation adjustment	$25,000		$14,000	'
Unrealized loss from cash flow hedge	-90,000	[1]	-261,000	'
Accumulated other comprehensive loss	-65,000		-247,000	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'	'
Unrealized loss from cash flow hedge	'		'	$261
[1]	During 2013, an amount of $261,000 in respect of unrealized loss from cash flow hedge was reclassified from accumulated other comprehensive loss into financial expenses.

TAXES_ON_INCOME_Narrative_Deta

TAXES ON INCOME (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Line Items]	'	'	'
Income tax rate	25.00%	25.00%	24.00%
Net operating loss carry forwards	$12	'	'
Income tax rate 2014 and thereafter	26.50%	'	'
Tax benefit terms	'The period of tax benefits, as described above, is subject to limitations of the earlier of 12 years from the commencement of production, or 14 years from the date of approval.	'	'
Tax exempt period	'10 years	'	'
Domestic Tax Authority [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax rate	25.00%	'	'
U.S Federal and State [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax rate	40.00%	'	'
Amended Rate Year One And Two [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax rate	10.00%	'	'
Amended Rate Year Three And Four [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax rate	7.00%	'	'
Amended Rate Year Five And Thereafter [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax rate	6.00%	'	'

TAXES_ON_INCOME_Schedule_of_In

TAXES ON INCOME (Schedule of Income (Loss) Before Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
TAXES ON INCOME [Abstract]	'	'	'
Israel	$10,414	$4,360	($1,036)
Non-Israeli Subsidiaries	814	416	273
INCOME (LOSS) BEFORE TAXES ON INCOME	$11,228	$4,776	($763)

TAXES_ON_INCOME_Schedule_of_Ta

TAXES ON INCOME (Schedule of Taxes on Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
TAXES ON INCOME [Abstract]	'	'	'
Non-Israeli Subsidiaries	$324	$180	$137
TAXES ON INCOME	$324	$180	$137

TAXES_ON_INCOME_Reconciliation

TAXES ON INCOME (Reconciliation of Theoretical Tax Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
TAXES ON INCOME [Abstract]	'	'	'
INCOME (LOSS) BEFORE TAXES ON INCOME	$11,228	$4,776	($763)
Theoretical tax expense (benefit)	2,807	1,194	-183
Increase (decrease) in taxes on income due to:	'	'	'
Computation of deferred taxes at a rate, which is different than statutory rate	-2,033	-1,157	166
Difference between income reported for tax purposes and income for financial reporting purposes - mainly dollar - NIS differences	-754	'	'
Non-deductible expenses - mainly share-based compensation expense	183	74	89
Different effective tax rates applicable to the subsidiaries	121	69	65
TAXES ON INCOME	$324	$180	$137
Statutory tax rate	25.00%	25.00%	24.00%

SUPPLEMENTARY_FINANCIAL_STATEM2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Receivable Other) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]	'	'
Advance to supplier	$1,153	$1,695
Institutions	1,065	1,024
Chief Scientist	77	153
Fair value of derivatives	1	251
Prepaid expenses and other	442	234
Accounts receivable - other, total	$2,738	$3,357

SUPPLEMENTARY_FINANCIAL_STATEM3

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals Other) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]	'	'
Employees and payroll related institutions	$2,470	$1,515
Provision for vacation and recreation pay	426	373
Royalties payable	57	23
Fair value of derivatives	222	261
Accrued expenses and sundry	3,203	910
Accounts payable and accruals, total	$6,378	$3,082

SUPPLEMENTARY_FINANCIAL_STATEM4

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]	'	'	'
Total expenses	$6,144	$4,876	$4,426
Less - participation and grants	197	265	566
Research and development - net	$5,947	$4,611	$3,860

SUPPLEMENTARY_FINANCIAL_STATEM5

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Finance Expenses) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]	'	'	'
Interest expenses and other bank charges	($595)	($657)	($590)
Interest income	50	'	'
Foreign exchange gain (losses) - net	-82	-102	22
Gain (losses) in respect of derivatives - net	96	220	152
FINANCIAL EXPENSES - net	($531)	($539)	($416)

FAIR_VALUE_MEASUREMENT_Narrati

FAIR VALUE MEASUREMENT (Narrative) (Details) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2009	Feb. 28, 2010
	Loans Payable Two [Member]	Interest Rate Swap [Member]
Debt Instrument [Line Items]	'	'
Principal amount of loan	$5.60	$5.60
Debt instrument, variable interest reference rate	'One month LIBOR	'
Interest spread on variable rate	5.05%	'
Effective interest rate	'	8.37%

FAIR_VALUE_MEASUREMENTS_Schedu

FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities) Details)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
	EUR (€)	Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 2 [Member]	Fair Value, Inputs, Level 2 [Member]
		USD ($)	USD ($)	USD ($)	USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'
Cash and cash equivalents - cash deposits and other	'	$74,430,000	$2,729,000	'	'
Interest rate swap (liabilities)	'	'	'	-132,000	-261,000
Forward contracts and currency options (liabilities)	'	'	'	-90,000	'
Forward contracts and currency options (assets)	'	'	'	1,000	251,000
Total fair value of assets, net of fair value liabilities	'	74,430,000	2,729,000	-221,000	-10,000
Forward exchange contracts, notional amount	€ 11,200,000	'	'	'	'

RELATED_PARTIES_Details

RELATED PARTIES (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2010
Related Party Transaction [Line Items]	'		'		'		'
Directors' fees	$143		$21		$6		'
Outstanding options	1,967,784		1,866,940		1,789,760		1,576,648
Stock options granted, exercise price	$2.51	[1]	$2.13	[1]	$2.08	[1]	$1.92	[1]
Options exercisable	1,747,532		1,335,112		1,067,668		'
Board of Directors [Member]	'		'		'		'
Related Party Transaction [Line Items]	'		'		'		'
Outstanding options	231,200		'		'		'
Stock options granted, exercise price	$4.12		'		'		'
Options exercisable	195,160		'		'		'
[1]	In dollars per share.

EARNINGS_LOSS_PER_SHARE_Narrat

EARNINGS (LOSS) PER SHARE (Narrative) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from diluted earnings per share calculation	13,600	1,100,580	-1,789,760
Warrant [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from diluted earnings per share calculation	'	-211,548	-155,448
Preferred shares [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from diluted earnings per share calculation	-12,905,312	-11,623,104	-11,342,468
Restricted Shares [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from diluted earnings per share calculation	52,020	'	'

EARNINGS_LOSS_PER_SHARE_Schedu

EARNINGS (LOSS) PER SHARE (Schedule of Basic Earnings Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
EARNINGS (LOSS) PER SHARE [Abstract]	'	'	'
Net income (loss)	$11,395	$4,782	($864)
Amount allocated to participating preferred shareholders	-6,439	-3,798	'
Net income (loss) applicable to ordinary shareholders - basic	$4,956	$984	($864)
Weighted average ordinary shares outstanding	7,544,387	2,996,624	2,965,481
Basic earnings (loss) per share	$0.66	$0.33	($0.29)

EARNINGS_LOSS_PER_SHARE_Schedu1

EARNINGS (LOSS) PER SHARE (Schedule of Diluted Earnings Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
EARNINGS (LOSS) PER SHARE [Abstract]	'	'	'
Net income (loss) applicable to ordinary shareholders - diluted	$4,956	$984	($864)
Weighted average ordinary shares outstanding	7,544,387	2,996,624	2,965,481
Add- additional shares from the assumed exercise of employee options and restricted shares vesting	1,742,069	465,253	'
Weighted average number of shares used in the computation of diluted earnings (loss) per share	9,286,456	3,461,877	2,965,481
Diluted earnings (loss) per share	$0.53	$0.28	($0.29)